

Processing text_000N_42449.tx.1: 1.

```
Phrase: 1.  
>>>> Phrase  
1  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (1000):  
    1000  1+ (1+ Score, WHO {MTH,NCI}) [clas]  
<<<< Mappings  
Processing text_000N_42449.tx.2: NCT03020030
```

```
Phrase: NCT03020030  
>>>> Phrase  
nct03020030  
<<<< Phrase
```

Processing text_000N_11586.tx.1: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

```
Phrase: Treatment of  
>>>> Phrase  
treatment of  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (833):  
    833  Treatment (Therapeutic procedure  
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N  
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})  
[topp]  
<<<< Mappings
```

```
Phrase: Newly  
>>>> Phrase  
newly  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (1000):  
    1000  newly {CHV} [idcn]  
<<<< Mappings
```

```
Phrase: Diagnosed  
>>>> Phrase  
diagnosed  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (1000):  
    1000  Diagnosed (Diagnosis  
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_  
NCI-GLOSS,NCI_NICHHD,SNOMEDCT_US}) [diap]  
<<<< Mappings
```

Phrase: Acute Lymphoblastic Leukemia in Children

>>>> Phrase

acute lymphoblastic leukemia in children

<<<< Phrase

>>>> Mappings

Meta Mapping (928):

 760 ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [tmco]

 926 Lymphoblastic leukemia in children {LCH_NW} [neop]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: Adolescents

>>>> Phrase

adolescents

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Adolescents (Adolescent (age group)

{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]

<<<< Mappings

Processing text_000N_11715.tx.1: Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children.

Phrase: Acute lymphoblastic leukemia

>>>> Phrase

acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia {CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET}) [neop]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: the most common cancer

>>>> Phrase

most common cancer

<<<< Phrase

>>>> Mappings

Meta Mapping (851):
660 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
660 Common (shared attribute {MTH,NCI}) [ftcn]
827 Cancer (Primary malignant neoplasm
{CHV,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: diagnosed in children.
>>>> Phrase
diagnosed in children
<<<< Phrase
>>>> Mappings

Meta Mapping (746):
790 Diagnosed (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_
NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
790 Children (Child
{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,
NDFRT,SNMI,SNOMEDCT_US}) [aggp]
<<<< Mappings

Processing text_000N_11715.tx.2: The cancer comes from a cell in the blood called a lymphocyte.

Phrase: The cancer
>>>> Phrase
cancer
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 Cancer (Primary malignant neoplasm
{CHV,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: comes from a cell
>>>> Phrase
comes from a cell
<<<< Phrase
>>>> Mappings

Meta Mapping (770):
770 Cell (Cells
{CHV,CSP,FMA,G0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA}) [cell]
<<<< Mappings

Phrase: in the blood
>>>> Phrase
blood
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 BLOOD (peripheral blood {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
<<<< Mappings

Phrase: called
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
966 Call (Call (Instruction) {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: a lymphocyte.

>>>> Phrase
lymphocyte
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Lymphocyte
{AOD,CHV,CSP,FMA,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US} [cell]
<<<< Mappings

Processing text_000N_11715.tx.3: Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections.

Phrase: Normal lymphocytes
>>>> Phrase
normal lymphocytes
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 NORMAL (Normal
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
861 Lymphocytes (Lymphocyte
{AOD,CHV,CSP,FMA,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [cell]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: produced in the bone marrow
>>>> Phrase
produced in the bone marrow
<<<< Phrase
>>>> Mappings
Meta Mapping (806):

806 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: along with other blood cells

>>>> Phrase

blood cells

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Blood Cells

{AOD,CHV,CSP,FMA,LCH,LCH_NW,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA} [cell]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: help

>>>> Phrase

help

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 help (Help document {HL7V3.0,MTH}) [inpr]

<<<< Mappings

Phrase: fight infections.

>>>> Phrase

fight infections

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 fight (Fighting {AOD,CHV,MTH,SNOMEDCT_US}) [socb]

861 Infections (Infection

{AOD,CHV,COSTAR,CST,DXP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHHD,PDQ,SNM,SNOMEDCT_US}) [patf]

<<<< Mappings

Processing text_000N_11715.tx.4: In ALL, the cancerous lymphocytes are called lymphoblasts.

Phrase: In ALL,
>>>> Phrase
acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDSC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
 [neop]
<<<< Mappings

Phrase: the cancerous lymphocytes
>>>> Phrase
cancerous lymphocytes
<<<< Phrase
>>>> Mappings
Meta Mapping (853):
 623 Cancer (Primary malignant neoplasm
{CHV,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [neop]
 861 Lymphocytes (Lymphocyte
{AOD,CHV,CSP,FMA,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [cell]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: called
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Call (Call (Instruction) {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: lymphoblasts.
>>>> Phrase
lymphoblasts
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Lymphoblasts (lymphoblast
{AOD,CHV,CSP,FMA,LNC,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US})
 [cell]
<<<< Mappings

Processing text_000N_11715.tx.5: They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells.

Phrase: They

>>>> Phrase

<<<< Phrase

Phrase: do

>>>> Phrase

<<<< Phrase

Phrase: not

>>>> Phrase

not

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Not (Negation {LNC,MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: help

>>>> Phrase

help

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 help (Help document {HL7V3.0,MTH}) [inpr]

<<<< Mappings

Phrase: fight infection

>>>> Phrase

fight infection

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 fight (Fighting {AOD,CHV,MTH,SNOMEDCT_US}) [socb]

861 N Infection, NOS (Communicable Diseases

{AOD,CHV,COSTAR,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_NICH,NDFT,NLMSubSyn,SNMI,SNOMEDCT_US}) [dsyn]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: crowd out

>>>> Phrase

crowd out

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

861 Crowd (Crowding {CHV,CSP,LCH_NW,LNC,MSH,MTH}) [socb]
694 Out (Removed {CHV,LNC,MTH,NCI}) [qlco]

<<<< Mappings

Phrase: the normal blood cells in the bone marrow

>>>> Phrase

the normal blood cells in the bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (724):

578 NORMAL (Normal
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
793 ~~BLOOD/BONE MARROW (Adverse Event Associated with Blood and
Bone Marrow {NCI,NCI_CTCAE})~~ [fndg]

744 Cells {CHV,CSP,FMA,GO,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA} [cell]

Meta Mapping (724):

578 NORMAL (Normal
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
744 BLOOD (peripheral blood {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
793 ~~cells bone marrow (Bone Marrow Cells~~
{CHV,FMA,LCH_NW,MSH,NCI,NLMSubSyn}) [cell]

<<<< Mappings

Phrase: so

>>>> Phrase

so

<<<< Phrase

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: the body

>>>> Phrase

body

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Body (Human body structure
{CHV,FMA,MTH,NLMSubSyn,SNOMEDCT_US}) [anst]

<<<< Mappings

Phrase: cannot

>>>> Phrase

<<<< Phrase

Phrase: make
>>>> Phrase
make
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Make (Make – Instruction Imperative {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: enough normal blood cells.
>>>> Phrase
normal blood cells
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 660 NORMAL (Normal
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
 901 Blood Cells
{AOD,CHV,CSP,FMA,LCH,LCH_NW,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI
,SNOMEDCT_US,UWDA} [cell]
<<<< Mappings
Processing text_000N_11715.tx.6: ALL is always fatal if it is not treated.

Phrase: ALL
>>>> Phrase
acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,N
CI_CTEP-SDC,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: always fatal
>>>> Phrase
always fatal
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Always (Always (frequency) {LNC,MTH,NCI}) [tmco]
 861 FATAL (Death Related to Adverse Event
{MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: if
>>>> Phrase
<<<< Phrase

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: treated.
>>>> Phrase
treated
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Treated (Treating {CHV,MTH,NCI}) [ftcn]
<<<< Mappings
Processing text_000N_11715.tx.7: With current treatments, most children and adolescents with this disease will be cured.

Phrase: With current treatments,
>>>> Phrase
current treatments
<<<< Phrase
>>>> Mappings
Meta Mapping (983):
983 Current Treatment (Current Therapy {NCI,NCI_CDISC,NLMSubSyn})
[topp]
<<<< Mappings

Phrase: most children
>>>> Phrase
children
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 Children (Child
{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,
NDFRT,SNMI,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: adolescents with this disease

>>>> Phrase

adolescents with this disease

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Adolescents (Adolescent (age group)
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
604 Disease {CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NDFRT,SNMI,SNOMEDCT_US} [dsyn]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: cured.

>>>> Phrase

cured

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Cured (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS})
[cnce]

<<<< Mappings

Processing text_000N_11715.tx.8: The standard treatment for ALL involves about 2 years of chemotherapy.

Phrase: The standard treatment for ALL

>>>> Phrase

the standard treatment for acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

581 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]

748 Treatment (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N

CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
647 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,N
CI_CTEP-SDC,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings

Phrase: involves about 2 years of chemotherapy.

>>>> Phrase

involves about 2 years of chemotherapy

<<<< Phrase

>>>> Mappings

Meta Mapping (672):

753 YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

753 Chemotherapy, NOS (Chemotherapy Regimen

{CCS,CCS_10,CHV,CSP,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [topp]

<<<< Mappings

Processing text_000N_11715.tx.9: The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL.

Phrase: The drugs

>>>> Phrase

drugs

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Drugs (Pharmaceutical Preparations {CHV,CSP,HL7V2.5,ICF,ICF-CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [phsu]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: used

>>>> Phrase

used

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 used (Used by {CHV,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: the doses of the drugs,
>>>> Phrase

the doses of the drugs

<<<< Phrase

>>>> Mappings

Meta Mapping (797):

797 doses drugs (Drug dose {AOD,CHV,LNC,NLMSubSyn,SNOMEDCT_US})
[qnco]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: similar

>>>> Phrase

similar

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Similar (Similarity {NCI}) [qlco]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: not identical for all children

>>>> Phrase

not identical for all children

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

593 Not (Negation {LNC,MTH,NCI}) [ftcn]

760 Identical {CHV,LNC,NCI,SNMI,SNOMEDCT_US} [qlco]

593 Children (Child

{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,
NDFRT,SNMI,SNOMEDCT_US}) [aggp]

<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: adolescents with ALL.

>>>> Phrase

adolescents with acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (816):

 760 Adolescents (Adolescent (age group)
 {AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
 695 N Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
 {CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDSC,N
 CI_CTEP-SDC,NCI_NCI-
 GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
 [neop]

<<<< Mappings

Processing text_000N_11715.tx.10: Some children and adolescents receive stronger treatment, especially during the first several months.

Phrase: Some children

>>>> Phrase

children

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Children (Child
 {AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,
 NDFRT,SNMI,SNOMEDCT_US}) [aggp]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: adolescents

>>>> Phrase

adolescents

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Adolescents (Adolescent (age group)
 {AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
 <<<< Mappings

Phrase: receive

>>>> Phrase

receive

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Receive {NCI,NCI_CDISC} [qlco]
<<<< Mappings

Phrase: stronger treatment,
>>>> Phrase
stronger treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
  661  Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
  861  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHDI,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: especially during the first several months.
>>>> Phrase
especially during the first several months
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  753  First (First (number) {CHV,LNC,MTH,SNOMEDCT_US}) [qnco]
  753  MONTHS (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings
Processing text_000N_11715.tx.11: A number of factors are used to
decide how strong the treatment should be to give the best chance for
cure.

Phrase: A number of factors
>>>> Phrase
a number of factors
<<<< Phrase
>>>> Mappings
Meta Mapping (772):
  770  *Number (Numbers
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_UCUM,SNMI,SNOMEDCT_US}) [qnco]
  636  factor A {CHV,MSH} [orch]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: used
>>>> Phrase
```

used
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 used (Used by {CHV,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
 {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: decide
>>>> Phrase
decide
<<<< Phrase

Phrase: how strong
>>>> Phrase
how strong
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: the treatment
>>>> Phrase
treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Treatment (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: give
>>>> Phrase
give
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Give (Give – dosing instruction imperative
{MTH,NCI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the best chance for cure.
>>>> Phrase
the best chance for cure
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 593 Best (best (quality) {MTH,NCI}) [qlco]
 760 Chance (chance {CHV,MTH,NCI}) [qlco]
 593 Cure (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [cnce]
<<<< Mappings
Processing text_000N_11715.tx.12: These factors are called "risk factors".

Phrase: These factors
>>>> Phrase
factors
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: called
>>>> Phrase
called

```
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Call (Call (Instruction) {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: "risk factors".
>>>> Phrase
risk factors
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  risk factors (risk factors - observation list {HL7V3.0,MTH})
[inpr]
<<<< Mappings
Processing text_000N_11715.tx.13: This trial is studying the use of a
new, updated set of risk factors to decide how strong the treatment
will be.

Phrase: This trial
>>>> Phrase
trial
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NC
I-GLOSS,SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: studying
>>>> Phrase
studying
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: the use of a new, updated set of risk factors
>>>> Phrase
the use of a new updated set of risk factors
<<<< Phrase
>>>> Mappings
Meta Mapping (711):
  760  Use of {MTH,SNOMEDCT_US} [ftcn]
```

```
573 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
540 Update {MTH,NCI} [tmco]
573 Set (Set scale {LNC,MTH}) [ftcn]
573 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
574 factor A {CHV,MSH} [orch]
<<<< Mappings
```

```
Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings
```

```
Phrase: decide
>>>> Phrase
decide
<<<< Phrase
```

```
Phrase: how strong
>>>> Phrase
how strong
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
  861 Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
<<<< Mappings
```

```
Phrase: the treatment
>>>> Phrase
treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings
```

```
Phrase: will
>>>> Phrase
<<<< Phrase
```

```
Phrase: be.
>>>> Phrase
<<<< Phrase
```

Processing text_000N_11715.tx.14: The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.

Phrase: The study

>>>> Phrase

study

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Study {MTH,NCI} [resa]

<<<< Mappings

Phrase: also

>>>> Phrase

also

<<<< Phrase

Phrase: will

>>>> Phrase

<<<< Phrase

Phrase: test

>>>> Phrase

test

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Test (Laboratory Procedures
{AOD,CHV,MEDLINEPLUS,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase: a new way of dosing

>>>> Phrase

a new way of dosing

<<<< Phrase

>>>> Mappings

Meta Mapping (593):

593 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

<<<< Mappings

Phrase: a chemotherapy drug

>>>> Phrase

chemotherapy drug

<<<< Phrase

>>>> Mappings

Meta Mapping (958):

958 Chemotherapy Drugs (Chemotherapy Drugs Administered

```
{MTH,MTHHH,NLMSubSyn}) [topp]
<<<< Mappings

Phrase: called
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Call (Call (Instruction) {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: pegaspargase
>>>> Phrase
pegaspargase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  PEGASPARGASE (pegaspargase
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF})
  [aapp,enzy,phsu]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: part of the standard treatment
>>>> Phrase
part of the standard treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (752):
  806  Part of {CHV,SNMI,SNOMEDCT_US} [spco]
  593  Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
  593  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
  [topp]
<<<< Mappings
```

Phrase: for ALL
>>>> Phrase
acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHDI,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
 [neop]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: based on checking levels of the drug
>>>> Phrase
based on checking levels of the drug
<<<< Phrase
>>>> Mappings
Meta Mapping (692):
 748 Based (Base - General Qualifier {MTH,NCI}) [idcn]
 748 Checking (Checking (action) {LNC,MTH,NCI,SNOMEDCT_US}) [acty]
 774 drug levels (Drug measurement
{CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: in the blood
>>>> Phrase
blood
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 BLOOD (peripheral blood {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: adjusting
>>>> Phrase
adjusting
<<<< Phrase

Phrase: the dose
>>>> Phrase

dose
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Dose # (Dose number:Number:Point in time:^Patient:Quantitative {LNC,MTH}) [clna]
<<<< Mappings

Phrase: based on the levels.
>>>> Phrase
based on the levels
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Based (Base – General Qualifier {MTH,NCI}) [idcn]
 770 Levels (Levels (qualifier value)
 {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings
Processing text_000N_20096.tx.1: There are a standard set of risk factors which are used to decide how strong treatment should be for a child with ALL.

Phrase: There
>>>> Phrase
there
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: a standard set of risk factors
>>>> Phrase
a standard set of risk factors
<<<< Phrase
>>>> Mappings
Meta Mapping (752):
 617 Standard Risk (Standard Risk Acute Leukemia {NCI}) [hlca]
 753 Set (Set scale {LNC,MTH}) [ftcn]
 600 factor A {CHV,MSH} [orch]
<<<< Mappings

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: used
>>>> Phrase
used
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 used (Used by {CHV,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: decide
>>>> Phrase
decide
<<<< Phrase

Phrase: how strong treatment
>>>> Phrase
how strong treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 660 Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
 827 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be for a child
>>>> Phrase
be for a child
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
 770 CHILD (Offspring {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS}) [famg]
<<<< Mappings

Phrase: with ALL.

>>>> Phrase

all

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 ALL (All
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]

<<<< Mappings

Processing text_000N_20096.tx.2: These risk factors include the child's age when the leukemia is diagnosed, how high the white blood cell count (WBC) is in the blood, whether or not leukemia cells are seen in the spinal fluid (referred to as Central Nervous System or CNS status), and whether or not the leukemia has certain abnormalities in their chromosomes (genetic material in the cell).

Phrase: These risk factors

>>>> Phrase

risk factors

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 risk factors (risk factors – observation list {HL7V3.0,MTH})
[inpr]

<<<< Mappings

Phrase: include

>>>> Phrase

include

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 include (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})
[ftcn]

<<<< Mappings

Phrase: the child's age

>>>> Phrase

child age

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 CHILD (Offspring {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]
861 AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SNOMEDCT_US}) [orga]

<<<< Mappings

Phrase: when
>>>> Phrase
<<<< Phrase

Phrase: the leukemia
>>>> Phrase
leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 LEUKEMIA (leukemia
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICH,NDFT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
 [neop]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: diagnosed
>>>> Phrase
diagnosed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Diagnosed (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NCI_NICH,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: how high
>>>> Phrase
how high
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 High (Abnormally high {CHV,HL7V3.0,MTH,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: the white blood cell count
>>>> Phrase
white blood cell count
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 Blood Cell Count, White (White Blood Cell Count procedure {AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase: is in the blood,

>>>> Phrase

is in the blood

<<<< Phrase

>>>> Mappings

Meta Mapping (770):

770 BLOOD (peripheral blood {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]

<<<< Mappings

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: not leukemia cells

>>>> Phrase

not leukemia cells

<<<< Phrase

>>>> Mappings

Meta Mapping (877):

660 Not (Negation {LNC,MTH,NCI}) [ftcn]

865 Leukemic Cells (Leukemic Cells Measurement {MTH,NCI,NCI_CDISC}) [lbpr]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: seen in the spinal fluid

>>>> Phrase

seen in the spinal fluid

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

760 Seen (seen {CHV,SNM,SNOMEDCT_US}) [qlco]

806 Spinal Fluid (Cerebrospinal Fluid

{AOD,CHV,CSP,CST,FMA,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsu]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: referred

>>>> Phrase

referred

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 referred (Referring {CHV,LNC,MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 TO (Tryptophanase
 {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: as

>>>> Phrase

<<<< Phrase

Phrase: Central Nervous System

>>>> Phrase

central nervous system

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 CENTRAL NERVOUS SYSTEM (CENTRAL NERVOUS SYSTEM DIAGNOSTIC
 RADIOPHARMACEUTICALS {ATC,MTH}) [irda]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: CNS status

>>>> Phrase

cns status

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 CNS (Central Nervous System
 {AOD,CHV,CSP,CST,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-}

GLOSS,OMIM,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]
 861 Status {CHV,HL7V3.0,LNC,MTH,NCI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: whether
>>>> Phrase
<<<< Phrase

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: the leukemia
>>>> Phrase
leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 N LEUKEMIA (leukemia
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
[neop]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: certain abnormalities in their chromosomes

>>>> Phrase

certain abnormalities in their chromosomes

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

 593 Certain (Certain (qualifier value)
{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

 797 N abnormalities chromosomes (Congenital chromosomal disease
{CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME
DCT_US}) [cgab,dsyn]

<<<< Mappings

Phrase: (genetic material in the cell

>>>> Phrase

genetic material in the cell

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

 806 Genetic material (Genetic Materials {CHV,MSH,SNOMEDCT_US})
[gngm]

 593 Cell (Cells
{CHV,CSP,FMA,G0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA}) [cell]

<<<< Mappings

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_20096.tx.3: Another risk factor is the amount of leukemia in the marrow that can be measured by a special laboratory test called "MRD" (Minimal Residual Disease) after the first month of treatment.

Phrase: Another risk factor

>>>> Phrase

risk factor

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Risk Factor (risk factors {AOD,CHV,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: the amount of leukemia

>>>> Phrase

the amount of leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

 770 Amount (Quantity)

{CHV,LNC,MTH,NCI,NCI_BRIDG,SNMI,SNOMEDCT_US}) [qnco]

 604 LEUKEMIA (leukemia)

{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICH,ND,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US}) [neop]

<<<< Mappings

Phrase: in the marrow

>>>> Phrase

marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: can

>>>> Phrase

<<<< Phrase

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: measured by a special laboratory test called "MRD"

>>>> Phrase

measured by a special laboratory test called mrd

<<<< Phrase

>>>> Mappings

Meta Mapping (712):

 744 Measured {CHV,LNC,MTH,NCI,NCI_FDA,SNOMEDCT_US} [qlco]

 744 Special {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

 770 Laboratory Test (Laboratory Procedures)

{AOD,CHV,MEDLINEPLUS,MTH,NCI,NCI_NCI-GLOSS,NCI_NICH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]

 711 Call (Decision {AOD,CHV,MTH,NCI}) [menp]

 744 MRD (Neoplasm, Residual

{CHV,CSP,MSH,MTH,NCI,ND,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US}) [neop]

<<<< Mappings

Phrase: (Minimal Residual Disease
>>>> Phrase
minimal residual disease
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Minimal Residual Disease (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: after the first month of treatment.
>>>> Phrase
after the first month of treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
586 First (First (number) {CHV,LNC,MTH,SNOMEDCT_US}) [qnco]
753 Month (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
586 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings
Processing text_000N_20096.tx.4: Over the last several years, new
factors have been identified which help predict how well a child's
leukemia may respond to treatment.

Phrase: Over the last several years,
>>>> Phrase
last several years
<<<< Phrase
>>>> Mappings
Meta Mapping (802):
660 Last {LNC,NCI} [qlco]
827 YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: new factors
>>>> Phrase
new factors
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
694 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

827 Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: identified
>>>> Phrase
identified
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Identified
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_NICHD,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: help
>>>> Phrase
help
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 help (Help document {HL7V3.0,MTH}) [inpr]
<<<< Mappings

Phrase: predict
>>>> Phrase
predict
<<<< Phrase

Phrase: how well
>>>> Phrase
how well
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Well (Good {CHV,LNC,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: a child's leukemia
>>>> Phrase

child leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 CHILD (Offspring {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]
 861 LEUKEMIA (leukemia
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICH,NDFT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
 [neop]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: respond to treatment.
>>>> Phrase
respond to treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings
Processing text_000N_20096.tx.5: These new risk factors include additional abnormalities in the genes of the leukemia cell, as well the amount of leukemia (MRD level) at second time point (about 2-3 months after starting treatment).

Phrase: These new risk factors
>>>> Phrase
new risk factors
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 660 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
 901 risk factors (risk factors - observation list {HL7V3.0,MTH})
 [inpr]
<<<< Mappings

Phrase: include
>>>> Phrase
include
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

```
1000    include (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})  
[ftcn]  
<<<< Mappings
```

Phrase: additional abnormalities in the genes of the leukemia cell,
>>>> Phrase

additional abnormalities in the genes of the leukemia cell

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (657):

```
575    Additional {LNC,MTH,NCI} [ftcn]
```

```
728    Gene Abnormality {NCI,NLMSubSyn} [comd]
```

```
562    Leukemic Cell {MTH,NCI} [cell]
```

```
<<<< Mappings
```

Phrase: as well

```
>>>> Phrase
```

well

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
1000    Well (Good {CHV,LNC,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
```

```
<<<< Mappings
```

Phrase: the amount of leukemia

```
>>>> Phrase
```

the amount of leukemia

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (708):

```
770    Amount (Quantity
```

```
{CHV,LNC,MTH,NCI,NCI_BRIDG,SNMI,SNOMEDCT_US}) [qnco]
```

```
604    LEUKEMIA (leukemia
```

```
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH  
_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-  
SDC,NCI_NCI-GLOSS,NCI_NICHHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})  
[neop]
```

```
<<<< Mappings
```

Phrase: (MRD level

```
>>>> Phrase
```

mrd level

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (888):

```
694    MRD (Neoplasm, Residual
```

```
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
```

```
861    Level (Levels (qualifier value)
```

```
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
```

Meta Mapping (694):

694 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: at second time point
>>>> Phrase
second time point
<<<< Phrase
>>>> Mappings

Meta Mapping (888):
660 Second (seconds
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [tmco]
901 Timepoint {MTH,NCI} [tmco]
<<<< Mappings

Phrase: (about 2-3 months after starting treatment
>>>> Phrase
about 2 3 months after starting treatment
<<<< Phrase
>>>> Mappings

Meta Mapping (656):
581 About (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US}) [qlco]
748 MONTHS (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
548 Start (Beginning {CHV,LCH,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
581 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase:).
>>>> Phrase
<<<< Phrase

Processing text_000N_20096.tx.6: In this trial, the investigators will
use the new risk factors along with old risk factors to decide how
strong the treatment will be.

Phrase: In this trial,
>>>> Phrase
trial
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NC

I-GLOSS, SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: the investigators
>>>> Phrase
investigators
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
 1000 Investigators (Research Personnel
 {CHV,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn})
 [prog]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: use
>>>> Phrase
use
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
 1000 use (utilization qualifier {MSH,MTH}) [ftcn]
<<<< Mappings

Phrase: the new risk factors along with old risk factors
>>>> Phrase
the new risk factors along with old risk factors
<<<< Phrase

>>>> Mappings

Meta Mapping (504):
 575 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
 598 risk factors (risk factors - observation list {HL7V3.0,MTH})
 [inpr]
 575 Old {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase

>>>> Mappings

Meta Mapping (1000):
 1000 TO (Tryptophanase
 {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: decide

```
>>>> Phrase
decide
<<<< Phrase

Phrase: how strong
>>>> Phrase
how strong
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
  861  Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: the treatment
>>>> Phrase
treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
  [topp]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be.
>>>> Phrase
<<<< Phrase
Processing text_000N_20096.tx.7: The goal is to better identify those
participants who might benefit from stronger treatment in order to
improve their chance for cure.

Phrase: The goal
>>>> Phrase
goal
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Goal (Act Mood - Goal {HL7V3.0,MTH}) [idcn]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: to
```

```
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: better
>>>> Phrase
better
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: identify
>>>> Phrase
identify
<<<< Phrase

Phrase: those participants
>>>> Phrase
participants
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  participants (Participant {AOD,CHV,MTH,NCI}) [popg]
<<<< Mappings

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: might
>>>> Phrase
<<<< Phrase

Phrase: benefit from stronger treatment
>>>> Phrase
benefit from stronger treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
 770  Benefit (benefit {AOD,CHV,NCI}) [qnco]
 737  Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]
 770  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
```

CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHDI,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: in order
>>>> Phrase
order
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Order (Permutation {MTH,NCI}) [qlco]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: improve
>>>> Phrase
improve
<<<< Phrase

Phrase: their chance for cure.
>>>> Phrase
their chance for cure
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Chance (chance {CHV,MTH,NCI}) [qlco]
 604 Cure (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [cnce]
<<<< Mappings
Processing text_000N_20096.tx.8: The investigators also hope to better identify participants who have a high chance of being cured with standard treatment in order to reduce their chance of side effects while maintaining the chance of cure.

Phrase: The investigators
>>>> Phrase
investigators
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Investigators (Research Personnel
{CHV,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn})

```
[prog]
<<<< Mappings

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: hope
>>>> Phrase
hope
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Hope (Hope (emotion) {AOD,CHV,MSH,MTH,NCI}) [menp]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: better
>>>> Phrase
better
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: identify
>>>> Phrase
identify
<<<< Phrase

Phrase: participants
>>>> Phrase
participants
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  participants (Participant {AOD,CHV,MTH,NCI}) [popg]
<<<< Mappings
```

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: a high chance of
>>>> Phrase
a high chance of
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
 604 High (Abnormally high {CHV,HL7V3.0,MTH,SNOMEDCT_US}) [qlco]
 770 Chance (chance {CHV,MTH,NCI}) [qlco]
<<<< Mappings

Phrase: being
>>>> Phrase
<<<< Phrase

Phrase: cured with standard treatment
>>>> Phrase
cured with standard treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 770 Cured (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS})
[cnce]
 770 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
 770 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: in order
>>>> Phrase
order
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Order (Permutation {MTH,NCI}) [qlco]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: reduce
>>>> Phrase
reduce
<<<< Phrase

Phrase: their chance of side effects
>>>> Phrase
their chance of side effects
<<<< Phrase
>>>> Mappings
Meta Mapping (745):
  760  Chance (chance {CHV,MTH,NCI}) [qlco]
  640  side effects (aspects of adverse effects {MSH,MTH}) [ftcn]
<<<< Mappings

Phrase: while
>>>> Phrase
<<<< Phrase

Phrase: maintaining
>>>> Phrase
maintaining
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Maintain (Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI}) [acty]
<<<< Mappings

Phrase: the chance of cure.
>>>> Phrase
the chance of cure
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
  770  Chance (chance {CHV,MTH,NCI}) [qlco]
  604  Cure (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [cnce]
<<<< Mappings
Processing text_000N_6971.tx.1: This trial also aims to study the
dosing of a drug called pegaspargase.

Phrase: This trial
>>>> Phrase
trial
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (1000):
    1000 Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI
I-GLOSS,SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: aims
>>>> Phrase
aims
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Aims (Aim (idea) {MTH,NCI}) [idcn]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: study
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: the dosing of a drug
>>>> Phrase
the dosing of a drug
<<<< Phrase
>>>> Mappings
Meta Mapping (797):
    797 dosing drug (Drug dose {AOD,CHV,LNC,NLMSubSyn,SNOMEDCT_US})
[qnco]
<<<< Mappings

Phrase: called
```

```
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Call (Decision {AOD,CHV,MTH,NCI}) [menp]
<<<< Mappings
```

Phrase: pegaspargase.

```
>>>> Phrase
pegaspargase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  PEGASPARGASE (pegaspargase
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF})
  [aapp,enzy,phsu]
<<<< Mappings
```

Processing text_000N_6971.tx.2: Pegaspargase is a chemotherapy drug that is an important part of ALL treatment but it is also can cause many side effects.

Phrase: Pegaspargase

```
>>>> Phrase
pegaspargase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  PEGASPARGASE (pegaspargase
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF})
  [aapp,enzy,phsu]
<<<< Mappings
```

Phrase: is

```
>>>> Phrase
<<<< Phrase
```

Phrase: a chemotherapy drug

```
>>>> Phrase
chemotherapy drug
<<<< Phrase
>>>> Mappings
Meta Mapping (958):
  958  Chemotherapy Drugs (Chemotherapy Drugs Administered
{MTH,MTHHH,NLMSubSyn}) [topp]
<<<< Mappings
```

Phrase: that

```
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: an important part of ALL treatment
>>>> Phrase
an important part of all treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (725):
  586  Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
  790  Part of {CHV,SNMI,SNOMEDCT_US} [spco]
  586  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
  [topp]
<<<< Mappings

Phrase: but
>>>> Phrase
<<<< Phrase

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: cause
>>>> Phrase
cause
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  cause (Etiology aspects {CHV,MSH,MTH}) [ftcn]
<<<< Mappings
```

Phrase: many side effects.
>>>> Phrase
side effects
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 side effects (aspects of adverse effects {MSH,MTH}) [ftcn]
<<<< Mappings
Processing text_000N_6971.tx.3: With the standard dose of pegaspargase, levels of the drug in the blood are higher than may be necessary to effectively treat leukemia.

Phrase: With the standard dose of pegaspargase,
>>>> Phrase
with the standard dose of pegaspargase
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 753 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
 753 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDSC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qncos]
 586 PEGASPARGEASE (pegaspargase
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF})
 [aapp,enzu,phsu]
<<<< Mappings

Phrase: levels of the drug
>>>> Phrase
levels of the drug
<<<< Phrase
>>>> Mappings
Meta Mapping (819):
 819 drug levels (Drug measurement
{CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: in the blood
>>>> Phrase
blood
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 BLOOD (In Blood {MSH,MTH}) [bdsu]
<<<< Mappings

Phrase: are
>>>> Phrase

<<<< Phrase

Phrase: higher than

>>>> Phrase

higher than

<<<< Phrase

>>>> Mappings

Meta Mapping (833):

833 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: may

>>>> Phrase

<<<< Phrase

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: necessary to

>>>> Phrase

necessary to

<<<< Phrase

Phrase: effectively

>>>> Phrase

effectively

<<<< Phrase

Phrase: treat

>>>> Phrase

treat

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 TREAT (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Phrase: leukemia.

>>>> Phrase

leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 LEUKEMIA (leukemia

{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-

SDC,NCI_NCI-GLOSS,NCI_NICHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
[neop]
<<<< Mappings
Processing text_000N_6971.tx.4: On this research study, the
investigators will be comparing the standard dose of pegaspargase with
a new way of dosing the drug based on levels of the drug that we can
measure in the blood.

Phrase: On this research study,
>>>> Phrase
research study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 research study {AOD,CHV,LCH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}
[resa]
<<<< Mappings

Phrase: the investigators
>>>> Phrase
investigators
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Investigators (Research Personnel
{CHV,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn})
[prog]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: comparing
>>>> Phrase
comparing
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Compare (Comparison {LNC,NCI}) [acty]
<<<< Mappings

Phrase: the standard dose of pegaspargase
>>>> Phrase
the standard dose of pegaspargase
<<<< Phrase

>>>> Mappings
Meta Mapping (696):
 760 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
 760 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_UCUM,SNOMEDCT_US}) [qncos]
 593 PEGASPARGASE (pegaspargase
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF})
[aapp,enzu,phsu]
<<<< Mappings

Phrase: with a new way of dosing

>>>> Phrase
with a new way of dosing

<<<< Phrase

>>>> Mappings

Meta Mapping (586):

 586 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: the drug

>>>> Phrase

drug

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Drug (Pharmaceutical Preparations {CHV,CSP,HL7V2.5,ICF,ICF-CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [phsu]
<<<< Mappings

Phrase: based on levels of the drug

>>>> Phrase

based on levels of the drug

<<<< Phrase

>>>> Mappings

Meta Mapping (716):

 753 Based (Base - General Qualifier {MTH,NCI}) [idcn]
 783 drug levels (Drug measurement
{CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: we

>>>> Phrase

<<<< Phrase

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: measure in the blood.
>>>> Phrase
measure in the blood
<<<< Phrase
>>>> Mappings
Meta Mapping (769):
 769 Vascular measure {NLMSubSyn,SNOMEDCT_US} [lbtr]
<<<< Mappings
Processing text_000N_6971.tx.5: With the new way of doing, treatment will begin with a lower dose.

Phrase: With the new way of
>>>> Phrase
with the new way of
<<<< Phrase
>>>> Mappings
Meta Mapping (593):
 593 New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: doing
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: treatment
>>>> Phrase
treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Treatment (Therapeutic procedure {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: begin with a lower dose.

```
>>>> Phrase
begin with a lower dose
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
  760  Begin (Beginning {CHV,LCH,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
  790  Low dose {CHV,LNC,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_6971.tx.6: If the levels are high, the dose will
be decreased one more time; however, if at any time the levels are too
low, dosing will be switched back up to the standard dose.

Phrase: If
>>>> Phrase
<<<< Phrase

Phrase: the levels
>>>> Phrase
levels
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Levels (Levels (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: high,
>>>> Phrase
high
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  HIGH (Value Above Reference Range {MTH,NCI,NCI_CDISC}) [inpr]
<<<< Mappings

Phrase: the dose
>>>> Phrase
dose
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings
```

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: decreased
>>>> Phrase
decreased
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Decreased {CHV,MTH,SNMI,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: one more time
>>>> Phrase
one more time
<<<< Phrase
>>>> Mappings
Meta Mapping (913):
 913 one time {HL7V3.0} [inpr]
<<<< Mappings

Phrase: ; however,
>>>> Phrase
however
<<<< Phrase

Phrase: if at any time
>>>> Phrase
if at any time
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
 770 TIME (Time
 {CHV,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NICHHD,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: the levels
>>>> Phrase
levels
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Levels (Levels (qualifier value)
 {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: too low,
>>>> Phrase
too low
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Too low {LNC} [fndg]
<<<< Mappings

Phrase: dosing
>>>> Phrase
dosing
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: switched
>>>> Phrase
switched
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Switch (Switch Device Component {NCI,NCI_FDA}) [mnob]
<<<< Mappings

Phrase: back up to the standard dose.
>>>> Phrase
back up to the standard dose
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 753 BACK (Dorsal {CHV,FMA,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US,UWDA}) [spco]

586 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
586 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings
Processing text_000N_6971.tx.7: The goal of this research study is to learn whether this new way of dosing (starting at a lower dose and changing the dose based on drug levels in the blood) will decrease side effects but still be as effective as the standard dosing of the drug.

Phrase: The goal of this research study

>>>> Phrase

the goal of this research study

<<<< Phrase

>>>> Mappings

Meta Mapping (722):

753 Goal (Act Mood – Goal {HL7V3.0,MTH}) [idcn]
623 research study {AOD,CHV,LCH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}
[resa]
<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: learn

>>>> Phrase

learn

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 learn (Learning

{AOD,CHV,CSP,G0,LCH,LCH_NW,MSH,MTH,NCI,SNM,SNMI,SNOMEDCT_US}) [menp]

<<<< Mappings

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: this new way of dosing

```
>>>> Phrase
this new way of dosing
<<<< Phrase
>>>> Mappings
Meta Mapping (593):
  593  New {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: (starting at a lower dose
>>>> Phrase
starting at a lower dose
<<<< Phrase
>>>> Mappings
Meta Mapping (723):
  726  Start (Beginning {CHV,LCH,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
  623  Low dose {CHV,LNC,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: changing
>>>> Phrase
changing
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Changing {CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}
  [ftcn]
<<<< Mappings

Phrase: the dose
>>>> Phrase
dose
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_UCUM,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: based on drug levels
>>>> Phrase
based on drug levels
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
  770  Based (Base - General Qualifier {MTH,NCI}) [idcn]
```

833 drug levels (Drug measurement
{CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: in the blood

>>>> Phrase

blood

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BLOOD (In Blood {MSH,MTH}) [bdsu]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: will

>>>> Phrase

<<<< Phrase

Phrase: decrease

>>>> Phrase

decrease

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Decrease {CHV,MTH,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: side effects

>>>> Phrase

side effects

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 side effects (aspects of adverse effects {MSH,MTH}) [ftcn]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: still

>>>> Phrase

still

<<<< Phrase

Phrase: be as effective

>>>> Phrase

be as effective
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 effective (Effectiveness {CHV,LCH,LNC,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: as the standard dosing of the drug.
>>>> Phrase
as the standard dosing of the drug
<<<< Phrase
>>>> Mappings
Meta Mapping (706):
 581 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
 774 dosing drug (Drug dose {AOD,CHV,LNC,NLMSubSyn,SNOMEDCT_US})
[qnco]
<<<< Mappings

Processing text_000N_1853.tx.1: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Phrase: Treatment of
>>>> Phrase
treatment of
<<<< Phrase
>>>> Mappings
Meta Mapping (833):
 833 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: Newly
>>>> Phrase
newly
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 newly {CHV} [idcn]
<<<< Mappings

Phrase: Diagnosed
>>>> Phrase
diagnosed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Diagnosed (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_

```
NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: Acute Lymphoblastic Leukemia in Children
>>>> Phrase
acute lymphoblastic leukemia in children
<<<< Phrase
>>>> Mappings
Meta Mapping (928):
    760    ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [tmco]
        926    Lymphoblastic leukemia in children {LCH_NW} [neop]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Adolescents
>>>> Phrase
adolescents
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    Adolescents (Adolescent (age group)
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
<<<< Mappings
Processing text_000N_42449.tx.1: 2.

Phrase: 2.
>>>> Phrase
2
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    2+ (2+ Score, WHO {MTH,NCI}) [clas]
<<<< Mappings
Processing text_000N_42449.tx.2: NCT00042341

Phrase: NCT00042341
>>>> Phrase
nct00042341
<<<< Phrase
Processing text_000N_53654.tx.1: Phase II Study of Clofarabine in
Pediatric Acute Lymphoblastic Leukemia (ALL)

Phrase: Phase II Study of Clofarabine
>>>> Phrase
phase ii study of clofarabine
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (816):
  862  Phase II Study (Phase 2 Clinical Trials
  {CHV,CSP,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]
  593  CLOFARABINE (clofarabine
  {ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
  GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]
<<<< Mappings
```

Phrase: in Pediatric Acute Lymphoblastic Leukemia

```
>>>> Phrase
```

```
pediatric acute lymphoblastic leukemia
```

```
<<<< Phrase
```

```
>>>> Mappings
```

```
Meta Mapping (1000):
```

```
  1000  pediatric Acute lymphoblastic leukaemia (Leukemia,
  Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]
```

```
<<<< Mappings
```

Processing text_000N_4712.tx.1: Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.

Phrase: Clofarabine

```
>>>> Phrase
```

```
clofarabine
```

```
<<<< Phrase
```

```
>>>> Mappings
```

```
Meta Mapping (1000):
```

```
  1000  CLOFARABINE (clofarabine
  {ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
  GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]
```

```
<<<< Mappings
```

Phrase: (injection

```
>>>> Phrase
```

```
injection
```

```
<<<< Phrase
```

```
>>>> Mappings
```

```
Meta Mapping (1000):
```

```
  1000  injection (Injection of therapeutic agent
  {CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]
```

```
<<<< Mappings
```

Phrase:)

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: is

```
>>>> Phrase
```

<<<< Phrase

Phrase: approved by the Food and Drug Administration

>>>> Phrase

approved by the food and drug administration

<<<< Phrase

>>>> Mappings

Meta Mapping (808):

748 Approved {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

853 Food and Drug Administration (United States Food and Drug Administration {CHV,MSH,NCI,NCI_FDA,NCI_NCI-GLOSS}) [hcro]

<<<< Mappings

Phrase: for the treatment of pediatric patients 1

>>>> Phrase

for the treatment of pediatric patients 1

<<<< Phrase

>>>> Mappings

Meta Mapping (695):

581 paediatric (Pediatrics {CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]

757 Patient Treatment (HL7CommitteeIDInRIM <Patient Administration> {HL7V3.0,MTH,NLMSubSyn}) [inpr]

<<<< Mappings

Phrase: to 21 years old with relapsed acute lymphoblastic leukemia

>>>> Phrase

to 21 years old with relapsed acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (763):

779 21 year old (Adult {AOD,CHV,LNC,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]

626 Acute lymphoblastic Leukemia relapse (Acute lymphoblastic leukemia recurrent {MTH,NLMSubSyn}) [neop]

<<<< Mappings

Phrase: who

>>>> Phrase

<<<< Phrase

Phrase: have

>>>> Phrase

<<<< Phrase

Phrase: had

>>>> Phrase

<<<< Phrase

Phrase: at least 2 prior treatment regimens.

>>>> Phrase

at least 2 prior treatment regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (762):

660 Prior Treatment (Prior Therapy {NCI,NLMSubSyn}) [clna]
799 regimens (Regimen – CHV concept {CHV,MTH}) [inpr]

<<<< Mappings

Processing text_000N_4712.tx.2: The purpose of this study is to determine whether Clofarabine is safe and effective in the treatment of Acute Lymphoblastic Leukemia (ALL.)

Phrase: The purpose of this study

>>>> Phrase

the purpose of this study

<<<< Phrase

>>>> Mappings

Meta Mapping (844):

844 purpose of study {AOD} [resa]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 T0 (Tryptophanase {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: determine

>>>> Phrase

determine

<<<< Phrase

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: Clofarabine

>>>> Phrase

clofarabine

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 CLOFARABINE (clofarabine
{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: safe
>>>> Phrase
safe
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: effective in the treatment of Acute Lymphoblastic Leukemia
>>>> Phrase

effective in the treatment of acute lymphoblastic leukemia
<<<< Phrase

>>>> Mappings

Meta Mapping (738):

767 effective treatment (Treatment Effectiveness
{AOD,CHV,MSH,NCI,NLMSubSyn}) [qlco]
633 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings

Phrase: (ALL.

>>>> Phrase
acute lymphoblastic leukemia
<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Processing text_000N_3677.tx.1: This is a non-randomized, open label, Phase II study of Clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia (ALL).

Phrase: This

>>>> Phrase

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a non-randomized, open label, Phase II study of Clofarabine
>>>> Phrase

a non randomized open label phase ii study of clofarabine

<<<< Phrase

>>>> Mappings

Meta Mapping (744):

573 Non (Negation {LNC,MTH,NCI}) [ftcn]

573 Randomized (Randomization {CHV,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [resa]

777 Open Label Study {NCI,NCI_CDISC,NCI_NCI-GLOSS} [resa]

593 Phase II (Stage level 2

{CHV,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpr]

573 CLOFARABINE (clofarabine

{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]

Meta Mapping (744):

573 Non (Negation {LNC,MTH,NCI}) [ftcn]

573 Randomized (Randomization {CHV,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [resa]

593 OPEN LABEL (Open Label Study {NCI,NCI_CDISC,NCI_NCI-GLOSS}) [resa]

782 Phase II Study (Phase 2 Clinical Trials

{CHV,CSP,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]

573 CLOFARABINE (clofarabine

{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]

<<<< Mappings

Phrase: in pediatric patients with refractory

>>>> Phrase

in pediatric patients with refractory

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

593 paediatric (Pediatrics

{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]

760 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

593 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: relapsed acute lymphoblastic leukemia (ALL).

>>>> Phrase

relapsed acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (916):

645 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]

923 N Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,N
CI_CTEP-SDC,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]

<<<< Mappings

Processing text_000N_3677.tx.2: Eligible patients must be in second or
subsequent relapse or be refractory.

Phrase: Eligible patients

>>>> Phrase

eligible patients

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Eligible {HL7V2.5,HL7V3.0,MTH,NCI} [qlco]

861 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: must

>>>> Phrase

<<<< Phrase

Phrase: be in second

>>>> Phrase

be in second

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

790 Second (seconds

{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: subsequent relapse

>>>> Phrase

subsequent relapse

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Subsequent Relapse {NCI,NCI_NICHD} [fndg]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: refractory.

>>>> Phrase

refractory

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Processing text_000N_3677.tx.3: Forty eligible patients will be enrolled in a Fleming 2-stage sequential study design in order to better assess the efficacy and safety of clofarabine in this patient population.

Phrase: Forty eligible patients

>>>> Phrase

forty eligible patients

<<<< Phrase

>>>> Mappings

Meta Mapping (851):

660 Forty {MTH,NCI,SNOMEDCT_US} [qnc0]

660 Eligible {HL7V2.5,HL7V3.0,MTH,NCI} [qlco]

827 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: enrolled in a Fleming 2-stage sequential study design
>>>> Phrase

enrolled in a fleming 2 stage sequential study design

<<<< Phrase

>>>> Mappings

Meta Mapping (734):

742 Fleming (fleming {CHV,SNMI}) [hcro]

781 Stage 2 Study (Phase 2 Clinical Trials

{CHV,CSP,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]

742 Sequential (Sequential - Sequence/Results Flag {HL7V2.5,MTH})
[idcn]

742 Design {MTH,NCI} [acty]

<<<< Mappings

Phrase: in order to

>>>> Phrase

order to

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 Order (Order (arrangement) {MTH,NCI}) [qlco]

<<<< Mappings

Phrase: better

>>>> Phrase

better

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]

<<<< Mappings

Phrase: assess

>>>> Phrase

assess

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Assess (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Phrase: the efficacy

```
>>>> Phrase
efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn}) [resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: safety of clofarabine
>>>> Phrase
safety of clofarabine
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790  SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
  623  CLOFARABINE (clofarabine
{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]
<<<< Mappings

Phrase: in this patient population.
>>>> Phrase
patient population
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  *^patient (Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]
  861  Population (geographic population {CHV,ICF,ICF-
CY,LCH,LCH_NW,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [qnco]
<<<< Mappings
Processing text_000N_29173.tx.1: A Phase II, Open Label Study of
Clofarabine in Pediatric Patients With Refractory or Relapsed Acute
Lymphoblastic Leukemia

Phrase: A Phase II,
>>>> Phrase
phase ii
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Phase II (Stage level 2
{CHV,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpr]
<<<< Mappings
```

Phrase: Open Label Study of Clofarabine
>>>> Phrase
open label study of clofarabine
<<<< Phrase
>>>> Mappings
Meta Mapping (816):
 862 Open Label Study {NCI,NCI_CDISC,NCI_NCI-GLOSS} [resa]
 593 CLOFARABINE (clofarabine
{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [nnon,phsu]
<<<< Mappings

Phrase: in Pediatric Patients With Refractory
>>>> Phrase
in pediatric patients with refractory
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 593 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
 760 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
 593 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: Relapsed Acute Lymphoblastic Leukemia
>>>> Phrase
relapsed acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
 645 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
 923 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,N
CI_CTEP-SDC,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings
Processing text_000N_22471.tx.1: 3.

Phrase: 3.
>>>> Phrase

3

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  <3 (<3 (qualifier value) {MTH,SNOMEDCT_US}) [qnco]
<<<< Mappings
Processing text_000N_22471.tx.2: NCT02228096
```

Phrase: NCT02228096

```
>>>> Phrase
nct02228096
<<<< Phrase
Processing text_000N_43088.tx.1: Study of Efficacy and Safety of
CTL019 in Pediatric ALL Patients
```

Phrase: Study of Efficacy

```
>>>> Phrase
study of efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (858):
  858  Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn} [resa]
<<<< Mappings
```

Phrase: and

```
>>>> Phrase
<<<< Phrase
```

Phrase: Safety of CTL019

```
>>>> Phrase
safety of ctl019
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790  SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
  623  CTL019 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
<<<< Mappings
```

Phrase: in Pediatric ALL Patients

```
>>>> Phrase
pediatric all patients
<<<< Phrase
>>>> Mappings
Meta Mapping (802):
  660  paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
  827  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
```

A,SNOMEDCT_US} [podg]

<<<< Mappings

Processing text_000N_20025.tx.1: This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant

Phrase: This

>>>> Phrase

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a single arm,

>>>> Phrase

single arm

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 SINGLE (Singular
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
861 ARM (Upper arm {AOD,CHV,FMA,HL7V2.5,ICF,ICF-CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET,UWDA}) [blor]

<<<< Mappings

Phrase: open-label,

>>>> Phrase

open label

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 OPEN LABEL (Open Label Study {NCI,NCI_CDISC,NCI_NCI-GLOSS})
[resa]

<<<< Mappings

Phrase: multi-center,

>>>> Phrase

multi center

<<<< Phrase

>>>> Mappings

Meta Mapping (916):

916 Multicentric {CHV,NCI,SNOMEDCT_US} [spco]

<<<< Mappings

Phrase: phase II

```
>>>> Phrase
phase ii
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Phase II (Stage level 2
{CHV,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: study
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: determine
>>>> Phrase
determine
<<<< Phrase

Phrase: the efficacy
>>>> Phrase
efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: safety of an experimental therapy
>>>> Phrase
safety of an experimental therapy
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (745):
    760    SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
    640    Therapy, Experimental (Therapies, Investigational
{CHV,MSH,NLMSubSyn}) [topp]
<<<< Mappings

Phrase: called
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
    966    Call (Call (Instruction) {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: CTL019 T-cells in pediatric patients
>>>> Phrase
ctl019 t cells in pediatric patients
<<<< Phrase
>>>> Mappings
Meta Mapping (776):
    833    CTL019 T-cells (CD19CAR-CD3zeta-4-1BB-expressing Autologous
T-lymphocytes {NCI}) [cell]
    586    paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
    586    Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with B-cell acute lymphoblastic leukemia,
>>>> Phrase
b cell acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    B Cell Acute lymphoblastic leukemia (Precursor B-cell
lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
```

<<<< Phrase

Phrase: refractory to standard chemotherapy regimen

>>>> Phrase

refractory to standard chemotherapy regimen

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

760 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]

593 Standard (Standard (document) {MTH,NCI}) [inpr]

640 Chemotherapy Regimen

{CCS,CCS_10,CHV,CSP,MTH,NCI,NLMSubSyn,SNOMEDCT_US} [topp]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: relapsed after allogeneic stem cell transplant

>>>> Phrase

relapsed after allogeneic stem cell transplant

<<<< Phrase

>>>> Mappings

Meta Mapping (789):

753 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]

753 Allogeneic (allogeneic {CHV,NCI,NCI_NCI-GLOSS,NCI_NICHHD})

[qlco]

833 Stem Cell Transplant (Stem cell transplant

{CHV,CSP,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI_NCI-GLOSS,NLMSubSyn})

[topp]

<<<< Mappings

Processing text_000N_12116.tx.1: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Phrase: A Phase II,

>>>> Phrase

phase ii

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Phase II (Stage level 2

{CHV,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpr]

<<<< Mappings

Phrase: Single Arm,

>>>> Phrase

single arm

```
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694 SINGLE (Singular
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
  861 ARM (Upper arm {AOD,CHV,FMA,HL7V2.5,ICF,ICF-
CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US
,SNOMEDCT_VET,UWDA}) [blor]
<<<< Mappings
```

```
Phrase: Multicenter Trial
>>>> Phrase
multicenter trial
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Trial, Multicentre (Multicenter Trials
{CHV,MSH,MTH,NLMSubSyn}) [resa]
<<<< Mappings
```

```
Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings
```

```
Phrase: Determine
>>>> Phrase
determine
<<<< Phrase
```

```
Phrase: the Efficacy
>>>> Phrase
efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]
<<<< Mappings
```

```
Phrase: and
>>>> Phrase
<<<< Phrase
```

```
Phrase: Safety of CTL019
```

```
>>>> Phrase
safety of ctl019
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
    790    SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
    623    CTL019 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
<<<< Mappings

Phrase: in Pediatric Patients With Relapsed
>>>> Phrase
in pediatric patients with relapsed
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
    593    paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
    760    Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
    593    relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Refractory B-cell Acute Lymphoblastic Leukemia
>>>> Phrase
refractory b cell acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (938):
    632    Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
    947    B Cell Acute lymphoblastic leukemia (Precursor B-cell
lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings
Processing text_000N_20518.tx.1: 4.

Phrase: 4.
>>>> Phrase
4
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    4+ (4+ Answer to question {LNC,MTH}) [fndg]
```

<<<< Mappings

Processing text_000N_20518.tx.2: NCT02819804

Phrase: NCT02819804

>>>> Phrase

nct02819804

<<<< Phrase

Processing text_000N_42449.tx.1: Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phrase: Nivolumab

>>>> Phrase

nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 NIVOLUMAB (nivolumab)

{ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_FDA, NDFRT, RXNORM, SNOMEDCT_US, USPMG, VANDF} [aapp, imft, phsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: Dasatinib in Treating Patients

>>>> Phrase

dasatinib in treating patients

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

770 DASATINIB (dasatinib)

{ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_DCP, NCI_FDA, NCI_NCI-GLOSS, NDFRT, PDQ, RXNORM, SNOMEDCT_US, USPMG, VANDF} [orch, phsu]

604 Treating {CHV, MTH, NCI} [ftcn]

604 Patients

{AOD, CHV, HL7V3.0, LCH, LCH_NW, LNC, MSH, MTH, NCI, NCI_CDISC, NCI_DICOM, NCI_FD, SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: With Relapsed

>>>> Phrase

relapsed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 relapsed (Relapsing course {CHV, MTH, SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
>>>> Phrase
refractory philadelphia chromosome positive acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (945):
629 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
954 Philadelphia chromosome-positive acute lymphoblastic leukemia {HPO,OMIM,SNOMEDCT_US} [neop]
<<<< Mappings
Processing text_000N_1853.tx.1: The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given to patients with relapsed/refractory philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Phrase: The purpose of this research study
>>>> Phrase
the purpose of this research study
<<<< Phrase
>>>> Mappings
Meta Mapping (774):
820 purpose of study {AOD} [resa]
586 Research (Research Activities {CHV,HL7V3.0,MSH,MTH,NCI,NLMSubSyn}) [resa]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 T0 (Tryptophanase {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: determine
>>>> Phrase

determine
<<<< Phrase

Phrase: the acceptable upper limit dose of nivolumab
>>>> Phrase
the acceptable upper limit dose of nivolumab
<<<< Phrase
>>>> Mappings
Meta Mapping (702):
 581 Acceptable {LNC,MTH,NCI} [qlco]
 581 UPPER (Upper
 {CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US,UWDA}) [spco]
 581 limit (Limited (extensiveness) {CHV,LNC,MTH,SNOMEDCT_US})
 [ftcn]
 748 Dose # (Dose number:Number:Point in
 time:^Patient:Quantitative {LNC,MTH}) [clna]
 581 NIVOLUMAB (nivolumab
 {ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
 G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: in combination with dasatinib
>>>> Phrase
in combination with dasatinib
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Combination (combination of objects {MTH,NCI}) [phob]
 604 DASATINIB (dasatinib
 {ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
 GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: given to patients
>>>> Phrase
given to patients
<<<< Phrase
>>>> Mappings

Meta Mapping (746):
790 GIVEN {LNC,MTH} [cnce]
790 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with relapsed/refractory philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

>>>> Phrase

relapsed refractory philadelphia chromosome positive acute
lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (909):

626 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
626 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
923 Philadelphia chromosome-positive acute lymphoblastic leukemia
{HP0,OMIM,SNOMEDCT_US} [neop]

<<<< Mappings

Processing text_000N_1853.tx.2: Nivolumab is currently Food and Drug Administration (FDA) approved for other cancers, but has not yet been investigated in Ph+ ALL.

Phrase: Nivolumab

>>>> Phrase

nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: currently Food and Drug Administration

>>>> Phrase

currently food and drug administration

<<<< Phrase

>>>> Mappings

Meta Mapping (928):

637 Currently (Current (present time)
{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
937 Food and Drug Administration (United States Food and Drug
Administration {CHV,MSH,NCI,NCI_FDA,NCI_NCI-GLOSS}) [hcro]

<<<< Mappings

Phrase: approved for other cancers,

>>>> Phrase

approved for other cancers

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

770 Approved {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

819 Cancer Other {LNC,NCI,NLMSubSyn} [neop]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: has

>>>> Phrase

<<<< Phrase

Phrase: not

>>>> Phrase

not

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Not (Negation {LNC,MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: yet

>>>> Phrase

yet

<<<< Phrase

Phrase: been

>>>> Phrase

<<<< Phrase

Phrase: investigated in Ph+ ALL.

>>>> Phrase

investigated in positive acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (789):

753 investigated (Investigates {CHV,SNOMEDCT_US}) [ftcn]

753 POSITIVE (Positive Finding {LNC,MTH,NCI,NCI_CDISC,NLMSubSyn})

[fndg]

833 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-}

GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})

[neop]

<<<< Mappings

Processing text_000N_1853.tx.3: Dasatinib is currently FDA approved for the treatment of Ph+ ALL, but has not yet been investigated in combination with nivolumab for this disease.

Phrase: Dasatinib

>>>> Phrase

dasatinib

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 DASATINIB (dasatinib)

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: currently FDA

>>>> Phrase

currently food and drug administration

<<<< Phrase

>>>> Mappings

Meta Mapping (928):

637 Currently (Current (present time))

{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]

937 Food and Drug Administration (United States Food and Drug Administration {CHV,MSH,NCI,NCI_FDA,NCI_NCI-GLOSS}) [hcro]

<<<< Mappings

Phrase: approved for the treatment of Ph+ ALL,

>>>> Phrase

approved for the treatment of positive acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (709):

742 Approved {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

742 treatment (therapeutic aspects {MSH,MTH,NLMSubSyn}) [ftcn]

742 POSITIVE (Positive Finding {LNC,MTH,NCI,NCI_CDISC,NLMSubSyn}) [fndg]

790 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia {CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})

[neop]

<<<< Mappings

Phrase: but
>>>> Phrase
<<<< Phrase

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: yet
>>>> Phrase
yet
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: investigated in combination
>>>> Phrase
investigated in combination
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 investigated (Investigates {CHV,SNOMEDCT_US}) [ftcn]
 790 Combination (combination of objects {MTH,NCI}) [phob]
<<<< Mappings

Phrase: with nivolumab for this disease.
>>>> Phrase
with nivolumab for this disease
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
 760 NIVOLUMAB (nivolumab
 {ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
 G,VANDF}) [aapp,imft,phsu]
 593 Disease {CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NCI_NICHD,NDFRT,SNMI,SNOMEDCT_US} [dsyn]
<<<< Mappings
Processing text_000N_1853.tx.4: There is evidence that dasatinib not

only blocks the Philadelphia chromosome or breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 (BCR–ABL) mutation, but also increases the activity of cells in your immune system.

Phrase: There

>>>> Phrase

there

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: evidence

>>>> Phrase

evidence

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Evidence {NCI} [idcn]

<<<< Mappings

Phrase: that dasatinib

>>>> Phrase

dasatinib

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 DASATINIB (dasatinib)

{ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_DCP, NCI_FDA, NCI_NCI-GLOSS, NDFRT, PDQ, RXNORM, SNOMEDCT_US, USPMG, VANDF}) [orch, phsu]

<<<< Mappings

Phrase: not

>>>> Phrase

not

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Not (Negation {LNC, MTH, NCI}) [ftcn]

<<<< Mappings

Phrase: only

>>>> Phrase

only

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Only (Only – dosing instruction fragment {MTH, SNOMEDCT_US})

[inpr]

<<<< Mappings

Phrase: blocks

>>>> Phrase

blocks

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Block (Block (unit of measure) {MTH,NCI}) [qnco]

<<<< Mappings

Phrase: the Philadelphia chromosome

>>>> Phrase

philadelphia chromosome

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 N Philadelphia Chromosome {CHV,CSP,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,NLMSubSyn} [patf]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1

>>>> Phrase

breakpoint cluster region abelson murine leukemia viral oncogene homolog 1

<<<< Phrase

>>>> Mappings

Meta Mapping (906):

821 BREAKPOINT CLUSTER REGION (BCR gene {CHV,HGNC,MTH,NCI,OMIM}) [gngm]

910 ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 (ABL1 gene {HGNC,MTH,NCI,OMIM}) [gngm]

<<<< Mappings

Phrase: (BCR-ABL

>>>> Phrase

bcr abl

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BCR/ABL (Fusion Proteins, bcr-abl {MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US}) [aapp,bacs]

<<<< Mappings

Phrase:)

```
>>>> Phrase
<<<< Phrase

Phrase: mutation,
>>>> Phrase
mutation
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    Mutation {AOD,CHV,CSP,LNC,MSH,MTH,SNM,SNMI,SNOMEDCT_US}
[genf]
<<<< Mappings

Phrase: but
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: increases
>>>> Phrase
increases
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    Increases (Increased {CHV,LNC,MTH,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: the activity of cells
>>>> Phrase
the activity of cells
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
    770    ACTIVITY (Activities
{CHV,ICD9CM,LNC,MTH,NCI,NCI_BRIDG,NLMSubSyn,SNOMEDCT_US}) [acty]
    604    Cells {CHV,CSP,FMA,GO,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA} [cell]
<<<< Mappings

Phrase: in your immune system.
>>>> Phrase
immune system
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    Immune System (Immune system {AOD,CHV,CSP,FMA,ICF,ICF-
```

CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US,UWDA}) [bdsy]
<<<< Mappings
Processing text_000N_1853.tx.5: Nivolumab increases T cells in your immune system, which allows your immune system to attack the cancer.

Phrase: Nivolumab
>>>> Phrase
nivolumab
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: increases
>>>> Phrase
increases
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Increases (Increased {CHV,LNC,MTH,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: T cells in your immune system,
>>>> Phrase
t cells in your immune system
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 T cells (T-Lymphocyte
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
 623 Immune System (Immune system {AOD,CHV,CSP,FMA,ICF,ICF-CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US,UWDA}) [bdsy]
<<<< Mappings

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: allows
>>>> Phrase
allows
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

```
    1000  allows (allowing {AOD,CHV}) [socb]
<<<< Mappings

Phrase: your immune system
>>>> Phrase
immune system
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Immune System (Immune system {AOD,CHV,CSP,FMA,ICF,ICF-
CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,SNOMEDCT_US,UWDA}) [bdsy]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: attack
>>>> Phrase
attack
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Attack (Onset of illness
{AOD,CHV,CSP,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: the cancer.
>>>> Phrase
cancer
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  CANCER (Malignant Neoplasms
{AIR,AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_NICHHD,NLMSubSyn,PDQ,SNM,SNMI,SNOMEDCT_US}) [neop]
<<<< Mappings
Processing text_000N_1853.tx.6: We think the combination of these
drugs will be more effective against your leukemia than either drug
used alone.

Phrase: We
```

```
>>>> Phrase
<<<< Phrase

Phrase: think
>>>> Phrase
think
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  think (Thinking, function {AOD,CHV,CSP,ICF,ICF-
CY,MSH,MTH,NCI,SNM,SNMI,SNOMEDCT_US}) [menp]
<<<< Mappings

Phrase: the combination of these drugs
>>>> Phrase
the combination of these drugs
<<<< Phrase
>>>> Mappings
Meta Mapping (797):
  797  Combination drugs (Drug Combinations {CHV,LNC,MSH,NLMSubSyn})
[phsu]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: more effective against your leukemia
>>>> Phrase
more effective against your leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  593  More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnc]
  760  effective (Effectiveness {CHV,LCH,LNC,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [qlco]
  593  LEUKEMIA (leukemia
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH
_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-
SDC,NCI_NCI-GLOSS,NCI_NICH,NDFR,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
[neop]
<<<< Mappings

Phrase: than either drug
>>>> Phrase
either drug
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  Either {LNC} [fndg]
  861  Drug (Pharmaceutical Preparations {CHV,CSP,HL7V2.5,ICF,ICF-
CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [phsu]
<<<< Mappings
```

```
Phrase: used
>>>> Phrase
used
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  used (Used by {CHV,SNOMEDCT_US}) [fndg]
<<<< Mappings
```

```
Phrase: alone.
>>>> Phrase
alone
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  alone (alone - group size {AOD,CHV,MTH}) [grpa]
<<<< Mappings
Processing text_000N_22471.tx.1: PRIMARY OBJECTIVES: I.
```

```
Phrase: PRIMARY OBJECTIVES
>>>> Phrase
primary objectives
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  Primary (Primary operation {MTH,NLMSubSyn,SNOMEDCT_US})
  [topp]
  861  objectives (objective (goal)
  {AOD,CHV,LNC,MSH,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings
```

```
Phrase: :
>>>> Phrase
<<<< Phrase
```

```
Phrase: I.
>>>> Phrase
i
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

1000 I- (Iodides
{AOD,CHV,DRUGBANK,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CRCH,NDFRT,SNMI,SNOME
DCT_US}) [inch]
<<<< Mappings

Processing text_000N_22471.tx.2: To determine the maximum tolerated dose (MTD) of nivolumab when given in combination with dasatinib in patients with relapsed/refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

Phrase: To
>>>> Phrase

to

<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: determine
>>>> Phrase
determine
<<<< Phrase

Phrase: the maximum tolerated dose (MTD) of nivolumab

>>>> Phrase
the maximum tolerated dose of nivolumab
<<<< Phrase
>>>> Mappings
Meta Mapping (780):
833 Maximum Tolerated Dose {CHV,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn} [qnco]
586 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: when
>>>> Phrase
<<<< Phrase

Phrase: given in combination

>>>> Phrase
given in combination
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
790 GIVEN {LNC,MTH} [cnce]
790 Combination (combination of objects {MTH,NCI}) [phob]
<<<< Mappings

Phrase: with dasatinib in patients
>>>> Phrase
with dasatinib in patients
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 DASATINIB (dasatinib)
 {ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_DCP, NCI_FDA, NCI_NCI-GLOSS, NDFRT, PDQ, RXNORM, SNOMEDCT_US, USPMG, VANDF} [orch, phsu]
 604 Patients
 {AOD, CHV, HL7V3.0, LCH, LCH_NW, LNC, MSH, MTH, NCI, NCI_CDISC, NCI_DICOM, NCI_FD_A, SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with relapsed/refractory Philadelphia chromosome positive
>>>> Phrase
relapsed refractory philadelphia chromosome positive
<<<< Phrase
>>>> Mappings
Meta Mapping (875):
 637 relapsed (Relapsing course {CHV, MTH, SNOMEDCT_US}) [tmco]
 637 Refractory (Unresponsive to Treatment {CHV, MTH, NCI, NCI_NCI-GLOSS, SNMI, SNOMEDCT_US}) [ftcn]
 884 Philadelphia Chromosome Positive (Philadelphia chromosome positive {CHV, MTH, NCI, NLMSubSyn}) [lbtr]
<<<< Mappings

Phrase: (Ph+) acute lymphoblastic leukemia (ALL).
>>>> Phrase
ph acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Ph+ acute lymphoblastic leukemia (Philadelphia chromosome-positive acute lymphoblastic leukemia {HPO, OMIM, SNOMEDCT_US}) [neop]
<<<< Mappings
Processing text_000N_22471.tx.3: SECONDARY OBJECTIVES: I.

Phrase: SECONDARY OBJECTIVES
>>>> Phrase
secondary objectives
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 secondary (Neoplasm Metastasis)
 {AOD, CHV, CSP, LCH_NW, LNC, MSH, MTH, NCI, NCI_NCI-GLOSS, NDFRT, NLMSubSyn} [neop]
 861 objectives (objective (goal))
 {AOD, CHV, LNC, MSH, MTH, NCI, SNOMEDCT_US} [inpr]

<<<< Mappings

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: I.
>>>> Phrase
i
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 I- (Iodides
{AOD,CHV,DRUGBANK,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CRCH,NDFRT,SNMI,SNOME
DCT_US}) [inch]
<<<< Mappings
Processing text_000N_22471.tx.4: To evaluate the toxicities and safety
profile of nivolumab and dasatinib in patients with relapsed/
refractory Ph+ ALL.

Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: evaluate
>>>> Phrase
evaluate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Evaluate (Evaluation
{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHHD,NLMSubSyn}) [hlca]
<<<< Mappings

Phrase: the toxicities
>>>> Phrase
toxicities
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 toxicities (Toxic effect
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,SNM,SNMI,SNOMEDCT_US}) [inpo]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: safety profile of nivolumab
>>>> Phrase
safety profile of nivolumab
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
604 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resal]
770 ~~Profile (Profile (lab procedure) {LNC,MTH}) [lbpr]~~
604 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: dasatinib in patients
>>>> Phrase
dasatinib in patients
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
790 DASATINIB (dasatinib
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
623 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with relapsed/refractory Ph+ ALL.
>>>> Phrase
relapsed refractory ph acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
632 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
632 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
901 Ph+ acute lymphoblastic leukemia (Philadelphia chromosome-
positive acute lymphoblastic leukemia {HPO,OMIM,SNOMEDCT_US}) [neop]
<<<< Mappings
Processing text_000N_22471.tx.5: II.

Phrase: II.

>>>> Phrase

ii

<<<< Phrase

Processing text_000N_22471.tx.6: To determine the rate of complete hematologic remission (CR) after three cycles of nivolumab and dasatinib.

Phrase: To

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: determine

>>>> Phrase

determine

<<<< Phrase

Phrase: the rate of complete hematologic remission

>>>> Phrase

the rate of complete hematologic remission

<<<< Phrase

>>>> Mappings

Meta Mapping (725):

 753 Rate {LNC,MTH,NCI} [qnco]
 617 Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
 [fndg]
 586 Hematologic {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [ftcn]

<<<< Mappings

Phrase: (CR

>>>> Phrase

cr

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Cr (Creatinine measurement
{CHV,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: after three cycles of nivolumab
>>>> Phrase
after three cycles of nivolumab
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
593 Three {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
760 Cycles (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]
593 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: dasatinib.

>>>> Phrase
dasatinib
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 DASATINIB (dasatinib
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
<<<< Mappings
Processing text_000N_22471.tx.7: III.

Phrase: III.
>>>> Phrase
iii
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 III (III (suffix) {MTH,NCI}) [qlco]
<<<< Mappings
Processing text_000N_22471.tx.8: To determine the rate of molecular
remission after three cycles of nivolumab and dasatinib.

Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzym]
<<<< Mappings

Phrase: determine

>>>> Phrase

determine

<<<< Phrase

Phrase: the rate of molecular remission

>>>> Phrase

the rate of molecular remission

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

760 Rate {LNC,MTH,NCI} [qnco]

593 Molecular {MTH,NCI} [qlco]

593 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: after three cycles of nivolumab

>>>> Phrase

after three cycles of nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

593 Three {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

760 Cycles (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]

593 NIVOLUMAB (nivolumab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: dasatinib.

>>>> Phrase

dasatinib

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 DASATINIB (dasatinib

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]

<<<< Mappings

Processing text_000N_22471.tx.9: IV.

Phrase: IV.

>>>> Phrase

intravenously

<<<< Phrase

Processing text_000N_22471.tx.10: To study the pharmacokinetics of nivolumab and dasatinib.

Phrase: To

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 T0 (Tryptophanase

{CSP, MSH, MTH, NCI, NDFRT, NLMSubSyn, PDQ, SNMI, SNOMEDCT_US}) [aapp, enzy]

<<<< Mappings

Phrase: study

>>>> Phrase

study

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Study {MTH, NCI} [resa]

<<<< Mappings

Phrase: the pharmacokinetics of nivolumab

>>>> Phrase

the pharmacokinetics of nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Pharmacokinetics (Drug Kinetics

{AOD, CHV, CSP, LCH, LCH_NW, MSH, MTH, NCI, NCI_CDISC, NCI_NCI-GLOSS}) [phsf]

604 NIVOLUMAB (nivolumab

{ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_FDA, NDFRT, RXNORM, SNOMEDCT_US, USPM

G, VANDF}) [aapp, imft, phsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: dasatinib.

>>>> Phrase

dasatinib

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 DASATINIB (dasatinib

{ATC, DRUGBANK, MSH, MTH, MTHSPL, NCI, NCI_DCP, NCI_FDA, NCI_NCI-GLOSS, NDFRT, PDQ, RXNORM, SNOMEDCT_US, USPMG, VANDF}) [orch, phsu]

<<<< Mappings

Processing text_000N_22471.tx.11: V.

Phrase: V.
>>>> Phrase
v
<<<< Phrase
Processing text_000N_22471.tx.12: To evaluate programmed cell death 1 (PD1) expression levels and saturation in the peripheral blood and bone marrow.

Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: evaluate
>>>> Phrase
evaluate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Evaluate (Evaluation
{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHED,NLMSubSyn}) [hlca]
<<<< Mappings

Phrase: programmed cell death 1 (PD1) expression levels
>>>> Phrase
programmed cell death 1 expression levels
<<<< Phrase
>>>> Mappings
Meta Mapping (890):
734 PROGRAMMED CELL DEATH 1 (PDCD1 gene {HGNC,MTH,NCI,NCI_NCI-HGNC,NLMSubSyn,OMIM}) [gngm]
793 expression level {HL7V3.0} [qnc0]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: saturation in the peripheral blood
>>>> Phrase
saturation in the peripheral blood
<<<< Phrase
>>>> Mappings
Meta Mapping (745):

760 Saturation (Saturated {AOD,CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[npop]
640 Peripheral Blood (peripheral blood
{CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: bone marrow.
>>>> Phrase
bone marrow
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
<<<< Mappings
Processing text_000N_22471.tx.13: VI.

Phrase: VI.
>>>> Phrase
vi
<<<< Phrase
Processing text_000N_22471.tx.14: To measure peripheral T-cell levels
and activation in response to treatment.

Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: measure
>>>> Phrase
measure
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Measure (Measurement
{AOD,CHV,CSP,LCH,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,NLMSubSyn,SNOMEDCT_US}
) [ftcn]
<<<< Mappings

Phrase: peripheral T-cell levels

>>>> Phrase

peripheral t cell levels

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

645 PERIPHERAL (Peripheral {CHV,HPO,LNC,NCI,NCI_CDISC,SNMI,SNOMEDCT_US,UWDA}) [spco]

694 T Cell (T-Lymphocyte {AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]

812 Levels (Levels (qualifier value) {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: activation in response

>>>> Phrase

activation in response

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 Activation (Activation action {CHV,LNC,MTH,NCI,NCI_NCI-GLOSS}) [acty]

623 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [fnndg]

<<<< Mappings

Phrase: to treatment.

>>>> Phrase

treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Treatment (Therapeutic procedure {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]

<<<< Mappings

Processing text_000N_22471.tx.15: TERTIARY OBJECTIVES: I.

Phrase: TERTIARY OBJECTIVES

>>>> Phrase

tertiary objectives

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Tertiary {CHV,NCI,SNMI,SNOMEDCT_US} [qnc0]
861 objectives (objective (goal)
{AOD,CHV,LNC,MSH,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: I.
>>>> Phrase
i
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 I- (Iodides
{AOD,CHV,DRUGBANK,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CRCH,NDFRT,SNMI,SNOME
DCT_US}) [inch]
<<<< Mappings
Processing text_000N_22471.tx.16: To evaluate the 30 day mortality
rate, overall survival (OS), progression free survival (PFS), and
duration of remission (DOR) one year after treatment with nivolumab
when given in combination with dasatinib in patients with relapsed/
refractory Ph+ ALL.

Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]
<<<< Mappings

Phrase: evaluate
>>>> Phrase
evaluate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Evaluate (Evaluation
{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHD,NLMSubSyn}) [hlca]
<<<< Mappings

Phrase: the 30 day mortality rate,
>>>> Phrase
30 day mortality rate
<<<< Phrase
>>>> Mappings

```
Meta Mapping (861):
  812  30% {LNC} [qnco]
  812  Day (day)
{AOD,CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,SNOMEDCT_US})
[tmco]
  861  Mortality rate (Mortality Vital Statistics
{AOD,CHV,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [qnco]
<<<< Mappings
```

Phrase: overall survival (OS),

>>>> Phrase

overall survival

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Overall Survival {NCI} [qnco]

<<<< Mappings

Phrase: progression free survival (PFS),

>>>> Phrase

progression free survival

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Progression-Free Survival {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn}

[qnco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: duration of remission (DOR) one year

>>>> Phrase

duration of remission one year

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

760 Duration (Duration (temporal concept)

{CHV,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]

593 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]

640 One year {SNOMEDCT_US} [tmco]

<<<< Mappings

Phrase: after treatment with nivolumab

>>>> Phrase

after treatment with nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

833 After-Treatment (Aftercare
{AOD,CHV,LCH,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [hlca]
604 NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: when

>>>> Phrase
<<<< Phrase

Phrase: given in combination

>>>> Phrase
given in combination
<<<< Phrase
>>>> Mappings

Meta Mapping (746):

790 GIVEN {LNC,MTH} [cnce]
790 Combination (combination of objects {MTH,NCI}) [phob]
<<<< Mappings

Phrase: with dasatinib in patients

>>>> Phrase
with dasatinib in patients
<<<< Phrase
>>>> Mappings

Meta Mapping (708):

770 DASATINIB (dasatinib
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
604 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with relapsed/refractory Ph+ ALL.

>>>> Phrase
relapsed refractory ph acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings

Meta Mapping (888):

632 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
632 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
901 Ph+ acute lymphoblastic leukemia (Philadelphia chromosome-
positive acute lymphoblastic leukemia {HPO,OMIM,SNOMEDCT_US}) [neop]
<<<< Mappings

Processing text_000N_22471.tx.17: II.

Phrase: II.

>>>> Phrase

ii

<<<< Phrase

Processing text_000N_22471.tx.18: To compare the OS between patients who receive a hematopoietic stem cell transplant and those who receive no further therapy following remission.

Phrase: To

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 T0 (Tryptophanase
{CSP, MSH, MTH, NCI, NDFRT, NLMSubSyn, PDQ, SNMI, SNOMEDCT_US}) [aapp, enzy]

<<<< Mappings

Phrase: compare

>>>> Phrase

compare

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Compare (Comparison {LNC, NCI}) [acty]

<<<< Mappings

Phrase: the OS between patients

>>>> Phrase

the overall survival between patients

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

 806 Overall Survival {NCI} [qnco]
 593 Patients
{AOD, CHV, HL7V3.0, LCH, LCH_NW, LNC, MSH, MTH, NCI, NCI_CDISC, NCI_DICOM, NCI_FD
A, SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: who

>>>> Phrase

<<<< Phrase

Phrase: receive

>>>> Phrase

receive

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Receive {NCI, NCI_CDISC} [qlco]

<<<< Mappings

Phrase: a hematopoietic stem cell transplant

>>>> Phrase

hematopoietic stem cell transplant

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Haematopoietic stem cell transplant {NLMSubSyn} [hlca]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: those who

>>>> Phrase

<<<< Phrase

Phrase: receive

>>>> Phrase

receive

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Receive {NCI,NCI_CDISC} [qlco]

<<<< Mappings

Phrase: no further therapy

>>>> Phrase

further therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Further {NCI} [spco]

861 Therapy (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Phrase: following

>>>> Phrase

following

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Following {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

<<<< Mappings

Phrase: remission.

>>>> Phrase

remission

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 N Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Processing text_000N_22471.tx.19: III.

Phrase: III.

>>>> Phrase

iii

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 III (III (suffix) {MTH,NCI}) [qlco]

<<<< Mappings

Processing text_000N_22471.tx.20: To evaluate for resistance mutations at the time of disease progression.

Phrase: To

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 TO (Tryptophanase {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: evaluate for resistance mutations

>>>> Phrase

evaluate for resistance mutations

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

 770 Evaluate (Evaluation {AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHED,NLMSubSyn}) [hlca]

 770 N Resistance (Resistance (Psychotherapeutic) {CHV,MTH}) [menp]

 770 Mutations (Mutation {AOD,CHV,CSP,LNC,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [genf]

<<<< Mappings

Phrase: at the time of disease progression.

>>>> Phrase

at the time of disease progression

<<<< Phrase

>>>> Mappings

Meta Mapping (722):
753 TIME (Time
{CHV,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NICHHD,SNOMEDCT_US}) [tmco]
623 N Disease progression NOS (Death Adverse Event Due to Disease
Progression Not Associated with More Specific CTCAE Term
{MTH,NCI_CTCAE}) [fnrg]
<<<< Mappings
Processing text_000N_22471.tx.21: OUTLINE: Patients receive dasatinib orally (PO) once daily (QD) on days 1–28 and nivolumab intravenously (IV) over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses.

Phrase: OUTLINE
>>>> Phrase
outline
<<<< Phrase

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: Patients
>>>> Phrase
patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: receive
>>>> Phrase
receive
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Receive {NCI,NCI_CDISC} [qlco]
<<<< Mappings

Phrase: dasatinib orally
>>>> Phrase
dasatinib orally
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
861 DASATINIB (dasatinib
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]

694 Orally (Oral {AOD,CHV,LNC,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [spco]
<<<< Mappings

Phrase: (PO
>>>> Phrase

po
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 PO (Oral {AOD,CHV,LNC,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [spco]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: once
>>>> Phrase
<<<< Phrase

Phrase: daily
>>>> Phrase

daily
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 Daily
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,SNMI,SNOMEDCT_US} [tmco]

<<<< Mappings

Phrase: (QD
>>>> Phrase

qd
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 QD (Daily
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,SNMI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: on days 1-28

>>>> Phrase
days 1 28
<<<< Phrase

```
>>>> Mappings
Meta Mapping (884):
  884  Day 1 (1 Day {LNC,MTH}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: nivolumab intravenously (IV) over 30 minutes on days 8
>>>> Phrase
  nivolumab intravenously over 30 minutes on days 8
<<<< Phrase
>>>> Mappings
Meta Mapping (677):
  578  NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF} [aapp,imft,phsu]
    770  30 minute (per 30 minutes {CHV,MTH,SNOMEDCT_US}) [tmco]
    578  DAYS (day
{AOD,CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,SNOMEDCT_US})
[tmco]
  Meta Mapping (677):
    578  NIVOLUMAB (nivolumab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPM
G,VANDF} [aapp,imft,phsu]
      600  30 days {LNC,MTH} [tmco]
      744  /minute (Per Minute
{CHV,MTH,NCI,NCI_CDISC,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 22 of course 1
>>>> Phrase
  22 of course 1
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
  770  Course {CHV,MTH,NCI,NCI_UCUM,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: and on days 1
>>>> Phrase
  and on days 1
<<<< Phrase
>>>> Mappings
Meta Mapping (816):
```

816 Day 1 (1 Day {LNC,MTH}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 15 of subsequent courses.

>>>> Phrase
15 of subsequent courses
<<<< Phrase
>>>> Mappings

Meta Mapping (722):

 770 Subsequent (Following {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
 770 Courses (Course {CHV,MTH,NCI,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Processing text_000N_22471.tx.22: Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal from the study for other reasons.

Phrase: Courses

>>>> Phrase

courses

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Courses (Course {CHV,MTH,NCI,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: repeat

>>>> Phrase

repeat

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Repeat (Repeat Pattern {HL7V2.5,MTH,NCI}) [tmco]

<<<< Mappings

Phrase: every 28 days in the absence of disease progression,

>>>> Phrase

every 28 days in the absence of disease progression

<<<< Phrase

>>>> Mappings

Meta Mapping (665):

 742 DAYS (day
 {AOD,CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,SNOMEDCT_US})
 [tmco]

 575 Absence (Absence (morphologic abnormality) {MTH,SNOMEDCT_US})
 [anab]

 598 N Disease progression NOS (Death Adverse Event Due to Disease)

Progression Not Associated with More Specific CTCAE Term
{MTH,NCI_CTCAE}) [fndg]
<<<< Mappings

Phrase: unacceptable toxicity,
>>>> Phrase
unacceptable toxicity
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Unacceptable {NCI} [qlco]
 861 toxicity (Toxicity aspects {MSH,MTH}) [qlco]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: withdrawal from the study
>>>> Phrase
withdrawal from the study
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Withdrawal (Withdraw (activity) {MTH,NCI}) [acty]
 604 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: for other reasons.

>>>> Phrase
reasons
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 reasons (Indication of (contextual qualifier)
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [idcn]
<<<< Mappings
Processing text_000N_22471.tx.23: After completion of study treatment,
patients are followed up at 30 days and then monthly for up to 1 year.

Phrase: After completion of study treatment,
>>>> Phrase
after completion of study treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (745):
 760 Completion (Complete
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
 631 Treatment Study {MTH,NCI,NCI_CDISC,NLMSubSyn} [resa]
Meta Mapping (745):

593 Study {MTH,NCI} [resa]
797 treatment completion (Treatment completed
{AOD,CHV,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: patients
>>>> Phrase
patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: followed up
>>>> Phrase
followed up
<<<< Phrase
>>>> Mappings
Meta Mapping (983):
 983 Follow-Up (Follow-Up Report {MTH,NCI,NCI_FDA}) [inpr]
<<<< Mappings

Phrase: at 30 days
>>>> Phrase
30 days
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 30 days {LNC,MTH} [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: then monthly for
>>>> Phrase
then monthly for
<<<< Phrase
>>>> Mappings
Meta Mapping (771):
 790 Then {MTH,NCI} [tmco]
 790 Monthly (Monthly (qualifier value))

{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: up to 1 year.

>>>> Phrase

1 year

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 1+ (1+ Score {MTH,NCI}) [qnco]

861 /Year (per year {CHV,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]

<<<< Mappings

Processing text_000N_22163.tx.1: Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Phrase: Phase Ib Study of Nivolumab

>>>> Phrase

phase ib study of nivolumab

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

640 Phase IB (Stage 1B {LNC,MTH,NCI,NLMSubSyn,SNOMEDCT_US})

[clas]

760 Study {MTH,NCI} [resa]

593 NIVOLUMAB (nivolumab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: Dasatinib in Patients

>>>> Phrase

dasatinib in patients

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 DASATINIB (dasatinib

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]

623 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD,A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

```
>>>> Phrase
relapsed refractory philadelphia chromosome positive acute
lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (909):
 626  relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
 626  Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
 923  Philadelphia chromosome-positive acute lymphoblastic leukemia
{HPO,OMIM,SNOMEDCT_US} [neop]
<<<< Mappings
Processing text_000N_53654.tx.1: 5.
```

```
Phrase: 5.
>>>> Phrase
5
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  >5 {SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_53654.tx.2: NCT01471782
```

```
Phrase: NCT01471782
>>>> Phrase
nct01471782
<<<< Phrase
Processing text_000N_43088.tx.1: Clinical Study With Blinatumomab in
Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor
Acute Lymphoblastic Leukemia
```

```
Phrase: Clinical Study With Blinatumomab
>>>> Phrase
clinical study with blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
 833  CLINICAL STUDY (Clinical Research
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_FDA,NCI_NCI-GLOSS,NLMSubSyn}) [resa]
 604  BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]
<<<< Mappings
```

```
Phrase: in Pediatric
>>>> Phrase
pediatric
<<<< Phrase
>>>> Mappings
```

Meta Mapping (1000):
1000 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

>>>> Phrase
adolescent patients with relapsed refractory b precursor acute lymphoblastic leukemia

<<<< Phrase
>>>> Mappings

Meta Mapping (766):

573 ADOLESCENT (Adolescent (age group)
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
739 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD,A,SNOMEDCT_US} [podg]
573 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
573 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
628 Precursor B-Lymphoblastic Leukemia (Precursor B-cell lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-GLOSS,NCI_NICH,NLMSubSyn,SNOMEDCT_US}) [neop]
573 ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDSC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Processing text_000N_20337.tx.1: The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this dose of blinatumomab is effective.

Phrase: The purpose of this study

>>>> Phrase
the purpose of this study

<<<< Phrase
>>>> Mappings

Meta Mapping (844):

844 purpose of study {AOD} [resa]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: determine
>>>> Phrase
determine
<<<< Phrase

Phrase: the dose of the bispecific T cell engager blinatumomab
>>>> Phrase
the dose of the bispecific t cell engager blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (665):
 742 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
 598 T Cell (T-Lymphocyte
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
 575 BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: (MT103
>>>> Phrase
mt103
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: in pediatric
>>>> Phrase
pediatric
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: adolescent patients with relapsed/refractory acute lymphoblastic leukemia

>>>> Phrase

adolescent patients with relapsed refractory acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (775):

578 ADOLESCENT (Adolescent (age group)

{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]

744 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

578 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,
SNMI,SNOMEDCT_US}) [ftcn]

639 Acute lymphoblastic Leukemia relapse (Acute lymphoblastic
leukemia recurrent {MTH,NLMSubSyn}) [neop]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: assess

>>>> Phrase

assess

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Assess (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: this dose of blinatumomab
>>>> Phrase
this dose of blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 DOSE (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]
 604 BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: effective.

>>>> Phrase

effective

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 effective (Effectiveness {CHV,LCH,LNC,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Processing text_000N_19806.tx.1: Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow in which the bone marrow makes too many abnormal immature lymphocytes.

Phrase: Childhood acute lymphoblastic leukemia

>>>> Phrase

childhood acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 childhood Acute lymphoblastic leukaemia (Leukemia, Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a type of cancer of the blood

>>>> Phrase

a type of cancer of the blood

<<<< Phrase

>>>> Mappings
Meta Mapping (747):
800 Type A blood (Blood group A (finding)
{ICD10CM,MTH,SNOMEDCT_US}) [fndg]
581 Cancer (Primary malignant neoplasm
{CHV,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: bone marrow in which
>>>> Phrase

bone marrow in which

<<<< Phrase

>>>> Mappings

Meta Mapping (833):

833 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
<<<< Mappings

Phrase: the bone marrow

>>>> Phrase

bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
<<<< Mappings

Phrase: makes

>>>> Phrase

makes

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Make (Make – Instruction Imperative {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: too

>>>> Phrase

too

<<<< Phrase

Phrase: many abnormal immature lymphocytes.

>>>> Phrase

abnormal immature lymphocytes

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

913 Abnormal lymphocytes (Atypical lymphocyte
{CHV,HPO,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
660 Immature {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US} [qlco]

Meta Mapping (901):

660 ABNORMAL (Abnormal {CHV,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [fndg]

901 Immature Lymphocytes (Immature Lymphocytes Measurement
{NCI,NCI_CDISC}) [lbpr]

<<<< Mappings

Processing text_000N_19806.tx.2: Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against cluster of differentiation (CD)19 expressing cells.

Phrase: Blinatumomab

>>>> Phrase

blinatumomab

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a bispecific single-chain antibody construct

>>>> Phrase

bispecific single chain antibody construct

<<<< Phrase

>>>> Mappings

Meta Mapping (840):

708 Bispecific Antibody (Antibodies, Bispecific {MSH,NCI,NCI_NCI-GLOSS,NDFRT}) [aapp,imft,phsu]

637 SINGLE (Singular
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]

637 Chain (chain of objects {LNC,MTH,NCI}) [idcn]

804 Construct {MTH,NCI} [clas]

<<<< Mappings

Phrase: designed

>>>> Phrase

designed

```
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Design {MTH,NCI} [acty]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: link
>>>> Phrase
link
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Link (Links List {MTH,NCI}) [inpr]
<<<< Mappings

Phrase: B cells
>>>> Phrase
b cells
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  B cells (B-Lymphocytes
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: T cells
>>>> Phrase
t cells
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  T cells (T-Lymphocyte
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
<<<< Mappings
```

Phrase: resulting in T cell activation

>>>> Phrase
resulting in t cell activation

<<<< Phrase

>>>> Mappings

Meta Mapping (893):

 806 Resulting in {MTH,SNMI,SNOMEDCT_US} [ftcn]
 862 T cell activation (T-Cell Activation {GO,NCI,NLMSubSyn})
 [celf]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: a cytotoxic T cell response against cluster of differentiation (CD)19 expressing cells.

>>>> Phrase
a cytotoxic t cell response against cluster of differentiation 19

expressing cells

<<<< Phrase

>>>> Mappings

Meta Mapping (698):

 618 cytotoxic T cell differentiation {GO,NLMSubSyn} [celf]
 736 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})
 [fndg]
 570 Cluster (entry - cluster {HL7V3.0,MTH}) [inpr]
 570 Cells {CHV,CSP,FMA,GO,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA} [cell]

<<<< Mappings

Processing text_000N_19806.tx.3: The purpose of this study is to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of escalating doses of blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor ALL, to select a dose and to investigate the efficacy and safety of that dose of blinatumomab in the above-mentioned patient population.

Phrase: The purpose of this study

>>>> Phrase
the purpose of this study

<<<< Phrase

>>>> Mappings

Meta Mapping (844):

 844 purpose of study {AOD} [resa]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: investigate
>>>> Phrase
investigate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 investigate (Investigates {CHV,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the pharmacokinetics (PK),
>>>> Phrase
pharmacokinetics
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Pharmacokinetics (Drug Kinetics
 {AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]
<<<< Mappings

Phrase: pharmacodynamics
>>>> Phrase
pharmacodynamics
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Pharmacodynamics {AOD,CHV,CSP,MTH,NCI} [biof]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: safety of escalating doses of blinatumomab
>>>> Phrase
safety of escalating doses of blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (676):
 753 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
 553 Escalate (Escalation {NCI}) [acty]
 586 Doses (Dosage)

```
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]
  586  BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]
<<<< Mappings
```

Phrase: in pediatric

```
>>>> Phrase
```

```
pediatric
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
  1000  paediatric (Pediatrics
```

```
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]
```

```
<<<< Mappings
```

Phrase: and

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: adolescent patients with relapsed/refractory B-precursor ALL,

```
>>>> Phrase
```

```
adolescent patients with relapsed refractory b precursor acute
lymphoblastic leukemia
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (766):

```
  573  ADOLESCENT (Adolescent (age group)
```

```
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
```

```
  739  Patients
```

```
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FA,
SNOMEDCT_US}) [podg]
```

```
  573  relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
```

```
  573  Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
```

```
  628  Precursor B-Lymphoblastic Leukemia (Precursor B-cell
lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-GLOSS,NCI_NICH,
NLMSubSyn,SNOMEDCT_US}) [neop]
```

```
  573  ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [tmco]
```

```
<<<< Mappings
```

Phrase: to

```
>>>> Phrase
```

```
to
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
    1000  To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: select
>>>> Phrase
select
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Select (Choose (action) {CHV,LNC,MTH,NCI}) [acty]
<<<< Mappings

Phrase: a dose
>>>> Phrase
dose
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Dose # (Dose number:Number:Point in
time:^Patient:Quantitative {LNC,MTH}) [clna]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: investigate
>>>> Phrase
investigate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  investigate (Investigates {CHV,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the efficacy
>>>> Phrase
efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

1000 EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: safety of
>>>> Phrase
safety of
<<<< Phrase
>>>> Mappings
Meta Mapping (833):
833 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
<<<< Mappings

Phrase: that dose of blinatumomab
>>>> Phrase
that dose of blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
770 Dose # (Dose number:Number:Point in time:^Patient:Quantitative {LNC,MTH}) [clna]
604 BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: in the above-mentioned patient population.
>>>> Phrase
above mentioned patient population
<<<< Phrase
>>>> Mappings
Meta Mapping (750):
645 *^patient (Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]
812 Population (Population Group
{CHV,LNC,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings
Processing text_000N_19806.tx.4: The phase 1 part of the study included the evaluation of four dose levels of blinatumomab with comprehensive PK/PD assessments and was separated in 2 parts: Phase 1 dose evaluation/escalation part to define the recommended phase 2 dose of blinatumomab in patients aged 2 to 17 years Phase 1 PK expansion part in patients aged < 18 years to further assess PK/PD at the recommended phase 2 dose.

Phrase: The phase 1 part of the study

>>>> Phrase

the phase 1 part of the study

<<<< Phrase

>>>> Mappings

Meta Mapping (773):

638 Phase 1 Study (Phase I Clinical Trials

{CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]

778 Part of {CHV,SNMI,SNOMEDCT_US} [spco]

<<<< Mappings

Phrase: included

>>>> Phrase

included

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 included (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})

[ftcn]

<<<< Mappings

Phrase: the evaluation of four dose levels of blinatumomab

>>>> Phrase

the evaluation of four dose levels of blinatumomab

<<<< Phrase

>>>> Mappings

Meta Mapping (677):

744 Evaluation

{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHID,NLMSubSyn} [hlca]

578 Four {MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

570 Dose Level (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]

578 BLINATUMOMAB (blinatumomab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US, VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: with comprehensive PK/PD assessments

>>>> Phrase

comprehensive pharmacokinetics pharmacodynamics assessments

<<<< Phrase

>>>> Mappings

Meta Mapping (833):

645 Comprehensive {NCI} [qlco]

645 Pharmacokinetics (Drug Kinetics

{AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]

645 Pharmacodynamics {AOD,CHV,CSP,MTH,NCI} [biof]

812 assessments (Evaluation procedure

{AOD,CHV,LNC,MTH,NCI,NCI_FDA,NLMSubSyn,SNOMEDCT_US}) [hlca]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: was

>>>> Phrase

<<<< Phrase

Phrase: separated in 2 parts

>>>> Phrase

separated in 2 parts

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Separated (Detached {CHV,MTH,NCI,NCI_CDISC,SNMI}) [ftcn]

770 PARTS (Part Dosing Unit {MTH,NCI,NCI_FDA}) [qnco]

<<<< Mappings

Phrase: :

>>>> Phrase

<<<< Phrase

Phrase: Phase 1 dose evaluation/escalation part

>>>> Phrase

phase 1 dose evaluation escalation part

<<<< Phrase

>>>> Mappings

Meta Mapping (839):

660 Phase 1 {CHV,SNOMEDCT_US} [tmco]

672 Dose Escalation {MTH,NCI} [ftcn]

632 Evaluation

{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHHD,NLMSubSyn} [hlca]

799 Part (Part Dosing Unit {MTH,NCI,NCI_FDA}) [qnco]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: define

>>>> Phrase

define

<<<< Phrase

Phrase: the recommended phase 2 dose of blinatumomab

>>>> Phrase

the recommended phase 2 dose of blinatumomab

<<<< Phrase

>>>> Mappings

Meta Mapping (719):

581 Recommended (Recommendation {CHV,HL7V3.0,LNC,MTH,NCI}) [idcn]

612 Phase 2 {CHV,NLMSubSyn,SNOMEDCT_US} [tmco]

748 Dose # (Dose number:Number.Point in

time.^Patient:Quantitative {LNC,MTH}) [clna]

581 BLINATUMOMAB (blinatumomab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: in patients

>>>> Phrase

patients

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: aged

>>>> Phrase

aged

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Aged (Elderly (population group)

{AOD,CHV,DXP,LCH,MSH,MTH,NCI,NCI_FDA,NLMSubSyn,SNMI,SNOMEDCT_US})

[popg]

<<<< Mappings

Phrase: 2 to 17 years Phase 1 PK expansion part

>>>> Phrase

2 to 17 years phase 1 pharmacokinetics expansion part

<<<< Phrase

>>>> Mappings

Meta Mapping (716):

762 2.17 {SNOMEDCT_US} [qnco]

742 YEARS (year

{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

764 Phase 1 {CHV,SNOMEDCT_US} [tmco]

742 Pharmacokinetics (Drug Kinetics

{AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]

742 Part (Part Dosing Unit {MTH,NCI,NCI_FDA}) [qnco]
<<<< Mappings

Phrase: in patients
>>>> Phrase
patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: aged
>>>> Phrase
aged
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Aged (Elderly (population group))
{AOD,CHV,DXP,LCH,MSH,MTH,NCI,NCI_FDA,NLMSubSyn,SNMI,SNOMEDCT_US}
[popg]
<<<< Mappings

Phrase: < 18 years to
>>>> Phrase
18 years to
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 YEARS (year)
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: further
>>>> Phrase
further
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Further {NCI} [spco]
<<<< Mappings

Phrase: assess
>>>> Phrase
assess
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 Assess (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: PK/PD at the recommended phase 2 dose.

>>>> Phrase

pharmacokinetics pharmacodynamics at the recommended phase 2 dose

<<<< Phrase

>>>> Mappings

Meta Mapping (709):

578 Pharmacokinetics (Drug Kinetics {AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]
744 Pharmacodynamics {AOD,CHV,CSP,MTH,NCI} [biof]
578 Recommended (Recommendation {CHV,HL7V3.0,LNC,MTH,NCI}) [idcn]
604 Phase 2 {CHV,NLMSubSyn,SNOMEDCT_US} [tmco]
578 ~~Dose # (Dose number.Number.Point in time.^Patient:Quantitative {LNC,MTH}) [clna]~~

<<<< Mappings

Processing text_000N_19806.tx.5: In this part additional participants were enrolled to ensure that 6 patients in each of the 2 older age groups (2-6 and 7-17 years) were analyzed for PK before recruitment of infants < 2 years of age began.

Phrase: In this part additional participants

>>>> Phrase

part additional participants

<<<< Phrase

>>>> Mappings

Meta Mapping (851):

660 Part (Part Dosing Unit {MTH,NCI,NCI_FDA}) [qnco]
660 Additional {LNC,MTH,NCI} [ftcn]
827 participants (Participant {AOD,CHV,MTH,NCI}) [popg]

<<<< Mappings

Phrase: were

>>>> Phrase

<<<< Phrase

Phrase: enrolled

>>>> Phrase

enrolled

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: ensure
>>>> Phrase
ensure
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 ENSURE (Ensure (product) {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,SNOMEDCT_US,VANDF}) [food]
<<<< Mappings

Phrase: that 6 patients in each of the 2 older age groups
>>>> Phrase
that 6 patients in each of the 2 older age groups
<<<< Phrase
>>>> Mappings
Meta Mapping (700):
 761 Old age patients (geriatric patients {CHV,NLMSubSyn}) [podg]
 571 Groups {CHV,HL7V3.0,MTH,NCI,SNOMEDCT_US} [idcn]
<<<< Mappings

Phrase: (2-6
>>>> Phrase
2 6
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 2.6 {SNOMEDCT_US} [qncos]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 7-17 years
>>>> Phrase
7 17 years
<<<< Phrase
>>>> Mappings
Meta Mapping (827):
 827 YEARS (year
 {CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmcos]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: were
>>>> Phrase

<<<< Phrase

Phrase: analyzed for PK

>>>> Phrase

analyzed for pharmacokinetics

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 Analyzed (Analysis {CHV,LCH,MTH,NCI,NCI_FDA,NCI_NCI-GLOSS})
[resa]

790 Pharmacokinetics (Drug Kinetics

{AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]

<<<< Mappings

Phrase: before recruitment of infants

>>>> Phrase

before recruitment of infants

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Recruitment {MTH,NCI} [acty]

604 Infants (Infant

{AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,
SNOMEDCT_US}) [aggp]

<<<< Mappings

Phrase: < 2 years of age

>>>> Phrase

2 years of age

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

833 > 2 years {LNC} [fndg]

604 AGE (Age

{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHHD,SNMI,SN
OMEDCT_US}) [orga]

Meta Mapping (783):

604 2+ (2+ Score, WHO {MTH,NCI}) [clas]

819 Age-Years {NCI,NCI_NCPDP} [tmco]

<<<< Mappings

Phrase: began.

>>>> Phrase

began

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 Begin (Beginning {CHV,LCH,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Processing text_000N_19806.tx.6: In the phase 2 extension cohort

(efficacy phase) of the study, eligible participants less than 18 years were enrolled according to a two-stage design and received blinatumomab at the recommended dose level (5/15).

Phrase: In the phase 2 extension cohort

>>>> Phrase

phase 2 extension cohort

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

694 Phase 2 {CHV,NLMSubSyn,SNOMEDCT_US} [tmco]

645 Extension {CHV,FMA,LNC,MTH,NCI,SNM,SNOMEDCT_US,UWDA} [ftcn]

812 COHORT (Cohort Studies

{AOD,CHV,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

<<<< Mappings

Phrase: (efficacy phase

>>>> Phrase

efficacy phase

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]

861 Phase {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: of the study,

>>>> Phrase

study

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Study {MTH,NCI} [resa]

<<<< Mappings

Phrase: eligible participants less than 18 years

>>>> Phrase

eligible participants less than 18 years

<<<< Phrase

>>>> Mappings

Meta Mapping (672):

586 Eligible {HL7V2.5,HL7V3.0,MTH,NCI} [qlco]

753 participants (Participant {AOD,CHV,MTH,NCI}) [popg]

586 YEARS (year

{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: were

>>>> Phrase

<<<< Phrase

Phrase: enrolled according to a two-stage design

>>>> Phrase

enrolled according to a two stage design

<<<< Phrase

>>>> Mappings

Meta Mapping (673):

748 according (Agreement {AOD,CHV,MTH,NCI}) [socb]

748 Two {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

748 Stage (Phase {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]

748 Design {MTH,NCI} [acty]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: received blinatumomab at the recommended dose level

>>>> Phrase

received blinatumomab at the recommended dose level

<<<< Phrase

>>>> Mappings

Meta Mapping (710):

581 RECEIVED (Receive {NCI,NCI_CDISC}) [qlco]

748 BLINATUMOMAB (blinatumomab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]

581 Recommended (Recommendation {CHV,HL7V3.0,LNC,MTH,NCI}) [idcn]

612 Dose Level (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]

<<<< Mappings

Phrase: (5/15

>>>> Phrase

5 15

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 >5 {SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_19806.tx.7: The study consisted of a screening period, a treatment period, and an End of Core Study visit 30 days after last dose of study medication.

Phrase: The study

>>>> Phrase

study

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Study {MTH,NCI} [resa]

<<<< Mappings

Phrase: consisted of a screening period,

>>>> Phrase

consisted of a screening period

<<<< Phrase

>>>> Mappings

Meta Mapping (685):

726 CONSIST (Consistency

{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]

760 Screening (Screening procedure

{CHV,LNC,MEDLINEPLUS,MSH,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [hlca]

760 Period (Period (temporal qualifier)

{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: a treatment period,

>>>> Phrase

treatment period

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Treatment (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N

CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHDI,NLMSubSyn,SNMI,SNOMEDCT_US})

[topp]

861 Period (Period (temporal qualifier)

{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: an End of Core Study visit 30 days

>>>> Phrase

an end of core study visit 30 days

<<<< Phrase

>>>> Mappings

Meta Mapping (719):
744 End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
578 Core (Core Device Component {MTH,NCI,NCI_FDA}) [medd]
578 Study {MTH,NCI} [resa]
578 Visit {MTH,NCI,SNM} [bhvr]
604 30 days {LNC,MTH} [tmco]
<<<< Mappings

Phrase: after last dose of study medication.

>>>> Phrase

after last dose of study medication

<<<< Phrase

>>>> Mappings

Meta Mapping (719):

586 Last {LNC,NCI} [qlco]
783 dose Medication (Drug dose
{AOD,CHV,LNC,NLMSubSyn,SNOMEDCT_US}) [qncos]
586 Study {MTH,NCI} [resa]

Meta Mapping (719):

586 Last {LNC,NCI} [qlco]
783 Medication dose (Medication XXX:Dosage:Point in
time:^Patient:Quantitative {LNC,MTH,NLMSubSyn}) [clna]
586 Study {MTH,NCI} [resa]

Meta Mapping (719):

586 Last {LNC,NCI} [qlco]
753 Dose # (Dose number:Number:Point in
time:^Patient:Quantitative {LNC,MTH}) [clna]
617 Medication study (Drug Evaluation
{AOD,CHV,COSTAR,CSP,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [resa]

<<<< Mappings

Processing text_000N_19806.tx.8: A treatment cycle consisted of a continuous intravenous (cIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks.

Phrase: A treatment cycle

>>>> Phrase

treatment cycle

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
861 Cycle (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]

<<<< Mappings

Phrase: consisted of a continuous intravenous (cIV) infusion

>>>> Phrase

consisted of a continuous intravenous infusion

```
<<<< Phrase
>>>> Mappings
Meta Mapping (764):
    719  CONSIST (Consistency
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
    833  Continuous Intravenous Infusion {MTH,NCI,NLMSubSyn} [topp]
<<<< Mappings

Phrase: over 4 weeks
>>>> Phrase
4 weeks
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  4 Weeks {HL7V2.5,MTH} [tmco]
<<<< Mappings

Phrase: followed by a treatment-free interval of 2 weeks.
>>>> Phrase
followed by a treatment free interval of 2 weeks
<<<< Phrase
>>>> Mappings
Meta Mapping (698):
    764  Followed by {CHV,MTH,SNMI,SNOMEDCT_US} [tmco]
    742  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
    742  Free (Free (available (qualifier)) {LNC,MTH}) [qlco]
    742  Interval {CHV,MTH,NCI,SNOMEDCT_US} [tmco]
    745  week 2 {LNC} [tmco]
<<<< Mappings
Processing text_000N_19806.tx.9: Participants who achieved complete
remission (CR) within 2 cycles of treatment could receive up to 3
additional consolidation cycles of blinatumomab.

Phrase: Participants
>>>> Phrase
participants
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  participants (Participant {AOD,CHV,MTH,NCI}) [popg]
<<<< Mappings

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: achieved
```

>>>> Phrase
achieved
<<<< Phrase

Phrase: complete remission (CR) within 2 cycles of treatment

>>>> Phrase
complete remission within 2 cycles of treatment
<<<< Phrase

>>>> Mappings

Meta Mapping (692):

 778 Complete Remission (In complete remission
 {AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
 [fndg]
 581 Cycles (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]
 581 Treatment (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]

<<<< Mappings

Phrase: could

>>>> Phrase

<<<< Phrase

Phrase: receive up to 3 additional consolidation

>>>> Phrase
receive up to 3 additional consolidation
<<<< Phrase

>>>> Mappings

Meta Mapping (672):

 753 Receive {NCI,NCI_CDISC} [qlco]
 753 Additional {LNC,MTH,NCI} [ftcn]
 753 Consolidation (Lung consolidation
 {CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]

<<<< Mappings

Phrase: cycles of blinatumomab.

>>>> Phrase
cycles of blinatumomab
<<<< Phrase

>>>> Mappings

Meta Mapping (746):

 790 Cycles (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]
 790 BLINATUMOMAB (blinatumomab
 {ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
 VANDF}) [aapp,imft,phsu]

<<<< Mappings

Processing text_000N_19806.tx.10: Instead of consolidation cycles with blinatumomab, participants could be withdrawn from blinatumomab treatment to receive chemotherapy or allogeneic HSCT as early as the

first cycle, at the discretion of the investigator.

Phrase: Instead of consolidation

>>>> Phrase

consolidation

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Consolidation (Lung consolidation

{CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]

<<<< Mappings

Phrase: cycles with blinatumomab,

>>>> Phrase

cycles with blinatumomab

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

 790 Cycles (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]

 790 BLINATUMOMAB (blinatumomab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]

<<<< Mappings

Phrase: participants

>>>> Phrase

participants

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 participants (Participant {AOD,CHV,MTH,NCI}) [popg]

<<<< Mappings

Phrase: could

>>>> Phrase

<<<< Phrase

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: withdrawn from blinatumomab treatment

>>>> Phrase

withdrawn from blinatumomab treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

 770 Withdrawn (Withdraw (activity) {MTH,NCI}) [acty]

 770 BLINATUMOMAB (blinatumomab

{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,

VANDF}) [aapp,imft,phsu]
 770 Treatment (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: receive
>>>> Phrase
receive
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Receive {NCI,NCI_CDISC} [qlco]
<<<< Mappings

Phrase: chemotherapy
>>>> Phrase
chemotherapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Chemotherapy (Pharmacotherapy
 {AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: allogeneic HSCT as early
>>>> Phrase
allogeneic hsct as early
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 604 Allogeneic (allogeneic {CHV,NCI,NCI_NCI-GLOSS,NCI_NICHHD})
 [qlco]
 770 HSCT (Hemopoietic stem cell transplant
 {CSP,LCH_NW,MSH,MTH,NCI,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [topp]

604 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: as the first cycle,

>>>> Phrase

first cycle

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 First (First (number) {CHV,LNC,MTH,SNOMEDCT_US}) [qnco]

861 Cycle (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]

<<<< Mappings

Phrase: at the discretion of the investigator.

>>>> Phrase

at the discretion of the investigator

<<<< Phrase

>>>> Mappings

Meta Mapping (586):

586 INVESTIGATOR (Research Personnel
{CHV,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn})

[prog]

<<<< Mappings

Processing text_000N_19806.tx.11: After the last treatment cycle and
End of Core Study visit, all participants were followed for efficacy
and survival for up to 24 months after treatment start.

Phrase: After the last treatment cycle

>>>> Phrase

last treatment cycle

<<<< Phrase

>>>> Mappings

Meta Mapping (851):

660 Last {LNC,NCI} [qlco]

660 Treatment (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

827 Cycle (event cycle {LCH_NW,MTH,NCI,NCI_UCUM}) [tmco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: End of Core Study visit,

>>>> Phrase

end of core study visit

<<<< Phrase

>>>> Mappings

Meta Mapping (733):
760 End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
593 Core (Core Device Component {MTH,NCI,NCI_FDA}) [medd]
593 Study {MTH,NCI} [resa]
593 Visit {MTH,NCI,SNM} [bhvr]
<<<< Mappings

Phrase: all participants

>>>> Phrase

participants

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 participants (Participant {AOD,CHV,MTH,NCI}) [popg]

<<<< Mappings

Phrase: were

>>>> Phrase

<<<< Phrase

Phrase: followed for efficacy

>>>> Phrase

followed for efficacy

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 followed (Followed by {CHV,MTH,SNMI,SNOMEDCT_US}) [tmco]

790 EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})

[resa]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: survival for

>>>> Phrase

survival for

<<<< Phrase

>>>> Mappings

Meta Mapping (833):

833 Survival (Continuance of life

{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Phrase: up to 24 months after treatment start.

>>>> Phrase

up to 24 months after treatment start

<<<< Phrase

>>>> Mappings

Meta Mapping (749):
612 Up to (Up {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
748 MONTHS (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
612 After-Treatment (Aftercare
{AOD,CHV,LCH,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [hlca]
581 Start (Beginning {CHV,LCH,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
<<<< Mappings
Processing text_000N_19806.tx.12: Participants who suffered a
hematological relapse of B-precursor ALL during their follow-up period
(at least 3 months after completion of treatment) had the possibility
for retreatment with blinatumomab.

Phrase: Participants
>>>> Phrase
participants
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 participants (Participant {AOD,CHV,MTH,NCI}) [popg]
<<<< Mappings

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: suffered
>>>> Phrase
suffered
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 suffered (Mental Suffering {AOD,CHV,MSH,MTH,SNOMEDCT_US})
[mobd]
<<<< Mappings

Phrase: a hematological relapse of B-precursor ALL
>>>> Phrase
a hematological relapse of b precursor acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings

Meta Mapping (743):
504 Haematology NOS (Haematology (discipline)
{CHV,CSP,LNC,MSH,MTH,NCI,OMIM,SNOMEDCT_US}) [bmod]
742 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
637 Precursor B-Lymphoblastic Leukemia (Precursor B-cell
lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [neop]
575 ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: during their follow-up period

>>>> Phrase

follow up period

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

734 Followup (follow-up {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [hlca]

827 Period (Period (temporal qualifier)

{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

Meta Mapping (901):

734 Follow-Up (Follow-Up Report {MTH,NCI,NCI_FDA}) [inpr]

827 Period (Period (temporal qualifier)

{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: (at least 3 months after completion of treatment

>>>> Phrase

at least 3 months after completion of treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (691):

744 MONTHS (month

{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

600 treatment completion (Treatment completed

{AOD,CHV,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: had

>>>> Phrase

<<<< Phrase

Phrase: the possibility for retreatment

>>>> Phrase

the possibility for retreatment

<<<< Phrase

>>>> Mappings

Meta Mapping (672):

699 Possible (Possibly Related to Intervention {MTH,NCI}) [qlco]

604 Retreatment (Retreatments {CHV,MSH,MTH,NCI}) [topp]

<<<< Mappings

Phrase: with blinatumomab.

>>>> Phrase

blinatumomab

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]
<<<< Mappings
Processing text_000N_35319.tx.1: A Single-Arm Multicenter Phase II
Study Preceded by Dose Evaluation to Investigate the Efficacy, Safety,
and Tolerability of the BiTE Antibody Blinatumomab (MT103) in
Pediatric and Adolescent Patients With Relapsed/Refractory B-Precursor
Acute Lymphoblastic Leukemia (ALL)
```

Phrase: A Single-Arm Multicenter Phase II Study

```
>>>> Phrase
single arm multicenter phase ii study
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (850):
```

```
  904  Single Arm Study (Single Group Study
{NCI,NCI_CDISC,NLMSubSyn}) [resa]
  549  Multicentric {CHV,NCI,SNOMEDCT_US} [spco]
  660  Phase II (Stage level 2
{CHV,LNC,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpr]
<<<< Mappings
```

Phrase: Preceded by Dose Evaluation

```
>>>> Phrase
preceded by dose evaluation
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
```

```
  770  preceded (Before {CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[tmco]
  770  Dose # (Dose number:Number:Point in
time:^Patient:Quantitative {LNC,MTH}) [clna]
  770  Evaluation
{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHHD,NLMSubSyn} [hlca]
<<<< Mappings
```

Phrase: to

```
>>>> Phrase
to
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

```
  1000  To {MTH,NCI} [qlco]
<<<< Mappings
```

Phrase: Investigate

```
>>>> Phrase
investigate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000   investigate (Investigates {CHV,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the Efficacy,
>>>> Phrase
efficacy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000   EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn}) [resa]
[resa]
<<<< Mappings

Phrase: Safety,
>>>> Phrase
safety
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000   SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
[resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Tolerability of the BiTE Antibody Blinatumomab
>>>> Phrase
tolerability of the bite antibody blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (697):
    753   TOLERABILITY (Tolerability Study {NCI,NCI_CDISC}) [resa]
    586   Bite (Dental Occlusion
{CHV,CSP,MSH,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US}) [ortf]
    586   Antibody (Antibodies {AOD,CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHHD,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA}) [aapp,imft]
    586   BLINATUMOMAB (blinatumomab
{ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: (MT103
>>>> Phrase
mt103
```

<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: in Pediatric
>>>> Phrase
pediatric
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Adolescent Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
>>>> Phrase
adolescent patients with relapsed refractory b precursor acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (766):
 573 ADOLESCENT (Adolescent (age group)
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
 739 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD,A,SNOMEDCT_US} [podg]
 573 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
 573 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
 628 Precursor B-Lymphoblastic Leukemia (Precursor B-cell lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [neop]
 573 ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: (ALL
>>>> Phrase
all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 ALL (All
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase